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sPLA2-X  secretory phospholipase A2 group X 
sVLDL  small very-low-density lipoprotein 
SM   sphingomyelin 
SMC   smooth muscle cell 
SR   scavenger receptor 
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ABSTRACT 
Atherosclerosis is a disease of the arteries; its characteristic features include 
chronic inflammation, extra- and intracellular lipid accumulation, extracellular 
matrix remodeling, and an increase in extracellular matrix volume. The 
underlying mechanisms in the pathogenesis of advanced atherosclerotic 
plaques, that involve local acidity of the extracellular fluid, are still 
incompletely understood. 
In this thesis project, my co-workers and I studied the different mechanisms by 
which local extracellular acidity could promote accumulation of the 
atherogenic apolipoprotein B-100 (apoB-100)-containing plasma lipoprotein 
particles in the inner layer of the arterial wall, the intima. We found that 
lipolysis of atherogenic apoB-100-containing plasma lipoprotein particles 
(LDL, IDL, and sVLDL) by the secretory phospholipase A2 group V (sPLA2-
V) enzyme, was increased at acidic pH. Also, the binding of apoB-100-
containing plasma lipoprotein particles to human aortic proteoglycans was 
dramatically enhanced at acidic pH. Additionally, lipolysis by sPLA2-V 
enzyme further increased this binding. Using proteoglycan-affinity 
chromatography, we found that sVLDL lipoprotein particles consist of 
populations, differing in their affinities toward proteoglycans. These 
populations also contained different amounts of apolipoprotein E (apoE) and 
apolipoprotein C-III (apoC-III); the amounts of apoC-III and apoE per particle 
were highest in the population with the lowest affinity toward proteoglycans.  
Since PLA2-modification of LDL particles has been shown to change their 
aggregation behavior, we also studied the effect of acidic pH on the monolayer 
structure covering lipoprotein particles after PLA2-induced hydrolysis. Using 
molecular dynamics simulations, we found that, in acidity, the monolayer is 
more tightly packed laterally; moreover, its spontaneous curvature is negative, 
suggesting that acidity may promote lipoprotein particles fusion. In addition to 
extracellular lipid accumulation, the apoB-100-containing plasma lipoprotein 
particles can be taken up by inflammatory cells, namely macrophages. Using 
radiolabeled lipoprotein particles and cell cultures, we showed that sPLA2-
V−modification of LDL, IDL, and sVLDL lipoproteins particles, at neutral or 
acidic pH, increased their uptake by human monocyte-derived macrophages.  
Introduction 
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I. INTRODUCTION 
Atherosclerosis develops slowly over decades due to both genetic and 
environmental factors (Lusis 2000). Early and intermediate atherosclerotic 
lesions are clinically silent, but some of them progress into advanced lesions 
prone to rupture that can cause disability or death. The first symptom of 
atherosclerosis often occurs as a sudden, potentially life-threatening 
cardiovascular event, and therefore research on the underlying mechanisms 
promoting atherosclerotic lesion progression is important. Complications of 
atherosclerosis are the most common cause of death in the Western world and 
the prevalence of the disease is increasing worldwide (Murray 1997, Lloyd-
Jones 2009).  
Apolipoprotein B-100-containing lipoprotein particles transport lipids in blood; 
in atherosclerosis, these lipoprotein particles accumulate in the inner layer of 
the arterial wall, the intima (Williams 1995, Williams 1998). A fraction of the 
circulating lipoprotein particles enters the intima through the endothelium in 
transcytotic vesicles, and in the intima they bind to the extracellular matrix 
components, mainly to arterial proteoglycans (Wight 2004). The matrix-bound 
lipoprotein particles can become oxidized in reactions catalyzed by metal ions 
or by enzymes, and become lipolyzed and proteolyzed by various enzymes 
secreted by intimal cells. Recently, in the mouse, secretory phospholipase A2 
group V (sPLA2-V) enzyme was shown to promote atherosclerotic lesion 
progression, and a Western-type high fat diet was shown to increase the 
secretion of this enzyme in the atherosclerotic lesions (Boström 2007, 
Rosengren 2006b). Further evidence is emerging on the protective role of 
phospholipase A2 (PLA2) inhibitors in the treatment of atherosclerosis in 
humans, and there are several ongoing clinical trials on novel inhibitors of 
PLA2 enzymes (Karakas 2009, Riley 2009, Rosenson 2009b).  
Lipoprotein particles bound to proteoglycans are more sensitive to a number of 
modifications (Wight 2004) and modified lipoprotein particles are prone to 
ingestion by inflammatory cells called macrophages. Uptake of modified 
lipoprotein particles by macrophages can result in the formation of highly 
oxygen-consuming foam cells loaded with lipid droplets, which sets off a 
cascade of inflammatory processes and leads to further lipid retention (Libby 
2002). Modified lipoprotein particles can also aggregate and fuse to form 
extracellular lipid droplets, which may be ingested by macrophages. 
Importantly, the intimal layer thickens due to intra- and extracellular lipid and 
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extracellular matrix accumulation. The intimal thickness may reach 1500 ± 350 
µm (Sluimer 2008), which greatly exceeds the maximal oxygen diffusion 
distance of 100-200 µm in tissues (Torres Filho 1994). This results in 
insufficient supply of oxygen to cells in intima. The combination of increased 
oxygen demand by highly oxygen-consuming activated cells and low oxygen 
supply leads to hypoxia in macrophage-rich areas (Sluimer 2009, Hultén 2009). 
Under hypoxia, cells switch to anaerobic metabolism and thus secrete 
metabolites acidifying the local extracellular milieu (Leppänen 2006, Naghavi 
2002).  
The purpose of the present thesis is to examine the influence of acidity on 
intra- and extracellular sPLA2-V-promoted atherogenic processes. In particular, 
this study investigates the role of sPLA2-V enzyme in the following processes: 
(1) lipolysis of lipoprotein particles, (2) acidity-induced changes in the surface 
monolayer of lipoprotein particles, (3) binding of lipoprotein particles to 
human aortic proteoglycans, and (4) uptake of lipoprotein particles by human 
monocyte-derived macrophages.  
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II. LITERATURE REVIEW 
1. PATHOGENESIS OF ATHEROSCLEROSIS 
The arterial wall consists of three distinct morphological layers separated by 
elastic laminae: intima, media, and adventitia. Atherosclerosis develops in the 
intimal layer from early fatty streaks to advanced fibrous plaques via a slow 
process starting already at the fetal stage, and is characterized by lipid and 
extracellular matrix accumulation and intimal layer thickening (Stary 2000). 
Importantly, arteries normally have both thin and thick segments, and 
atherosclerosis preferentially develops in the thick atherosclerotic-prone areas 
located near bifurcations of arteries and at the openings of vessel branches 
where arteries have adjusted their intimal thickness to equal flow at all points 
(Stary 2000). The intima is morphologically divided into two layers: a 
proteoglycan-rich layer (subjacent to the lumen) and an underlying 
musculoelastic layer (Fig. 1). The proteoglycan-rich intimal layer is composed 
of proteoglycans, collagens, and elastins, whereas the musculoelastic intimal 
layer is composed of smooth muscle cells (SMCs), and contains more elastins 
and collagens than the proteoglycan-rich intimal layer. The intima is separated 
from vascular lumen by a single layer of endothelial cells, and lipoproteins 
filtrate into the intima from blood through the endothelium in transcytotic 
vesicles (Steinberg 1985). In particular, transcytotic vesicles can carry 
lipoprotein particles having a diameter smaller than 75 nm (Nordestgaard 
1988), i.e., low-density lipoprotein (LDL), intermediate-density lipoprotein 
(IDL), and small very-low-density lipoprotein (sVLDL) particles. 
Once lipoproteins have entered the intima, they may bind to the extracellular 
matrix and are, therein, prone to modification by various enzymes and 
oxidizing agents (Wight 2004). The extracellular matrix of the proteoglycan-
rich intimal layer is mainly composed of arterial proteoglycans, and there is a 
highly specific interaction between proteoglycans and the apolipoprotein B-100 
(apoB-100) moiety of lipoproteins (Iverius 1972, Wight 2004, Skålen 2002), 
which may be enhanced by lipoprotein modification (Öörni 2000). Modified 
lipoproteins are recognized by inflammatory cells and trigger the recruitment 
of more monocytes into the intima, where the monocytes differentiate into 
arterial macrophages that take up modified lipoprotein particles (Galkina 
2009). Importantly, macrophages express, at their surface, scavenger receptors 
(SRs) (Goldstein 1979, Moore 2006) and also cell-surface proteoglycans 
Literature Review 
(Boyanovsky 2009a) that have a high affinity toward modified lipoprotein 
particles.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Accumulation of lipids in the atherosclerotic arterial intima. 
Uptake of modified lipoproteins into macrophages may be beneficial during the 
initial stages of atherogenesis as it scavenges potentially inflammatory 
modified lipoproteins, preventing them from accumulating in the arterial wall. 
However, the uptake of modified lipoproteins is unregulated and leads to 
massive lipoprotein internalization, thus transforming macrophages into highly 
oxygen-consuming lipid-loaded foam cells (Goldstein 1979, Björnheden 1987). 
The foam cells attract more monocytes into the intima, stimulate SMC 
migration to the intimal layer from the media, and secrete pro-inflammatory 
cytokines and reactive oxygen species resulting in an amplification of the local 
12  
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inflammatory response (Libby 2002). Thus, atherosclerotic intima resembles 
other chronic inflammatory sites in that it contains a large number of activated 
immune cells, such as monocyte-derived macrophages, mast cells, and T-cells 
(Libby 2002, Hansson 2005). The extracellular fluid in inflammatory tissues is 
known to be acidic (Lardner 2001). Thus, in analogy to other inflammatory and 
ischaemic sites, the atherosclerotic lesion areas, with clusters of inflammatory 
cells, have locally acidic extracellular pH (Naghavi 2002).  
Foam cells may aggregate and form a fatty streak, which is the first visible sign 
of the oversupply of lipids to the arterial intima (Stary 2000). However, in the 
earliest stage of human coronary atherosclerosis, extracellular clusters of 
modified and fused apoB-100-containing lipoprotein particles form deposits 
within the extracellular matrix of the proteoglycan-rich layer (Pasquinelli 1989, 
Nakashima 2007). In time, increasing numbers of lipid droplets accumulate 
both in foam cells and within the extracellular matrix. The lipid deposits found 
in the core regions of fibrous plaques are almost entirely extracellular. The 
extracellular lipid droplets may be derived from either the necrosis of cells 
containing intracellular lipid droplets or from direct formation of lipid droplets 
in the extracellular space. The latter possibility is supported by: 1) the size and 
composition of the extracellular lipid droplets, both of which differ from those 
of intracellular lipid droplets (Guyton 1990), and 2) the observation that 
extracellular lipid deposition may form independent of foam cell death 
(Nakashima 2007).  
During the progression of atherosclerotic lesions, the thickness of intima 
increases due to lipid accumulation, and, more importantly, due to increased 
deposition of the extracellular matrix components. Thus, the extracellular 
matrix is remodeled during lesions progression. SMCs play a key role in this 
remodeling by migrating from the media to the intima, where they proliferate 
and secrete extracellular matrix components (Doran 2008). Increased intimal 
thickness, which is beyond the oxygen diffusion distance, with the increased 
oxygen demand caused by activated macrophages, may lead to hypoxic 
conditions. Indeed, regions of severe hypoxia have been detected in advanced 
lesions, particularly at the junction of the proteoglycan and musculoelastic 
layers, where macrophage foam cells typically accumulate (Björnheden 1999, 
Sluimer 2008).  
Initially, no capillaries are found in the intimal layer; however hypoxia 
promotes angiogenesis, a process in which neovascular sprouts originating 
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from the adventitial vasa vasorum enter the lesion (Sluimer 2008). These new 
microvessels provide oxygen and nutrients, helping to restore the ATP levels in 
cells within lesions. Angiogenesis is also promoted by various growth factors, 
chemokines, cytokines, and proteinases present in the lesions (Fraisl 2009). 
However, neovascularization may be maladaptive and may be a 
pathophysiological consequence of lesion progression because the 
inflammatory cells may induce rupture of the fragile neovessels, thereby 
causing intraplaque hemorrhage and ensuing plaque destabilization (Ribatti 
2008, Sluimer 2009). Additionally, hypoxia plays a key role in many other 
atherogenic processes by also promoting lipid accumulation, inflammation, and 
depletion of ATP (Hultén 2009). Of particular interest are the observations of 
both hypoxia and local acidity in advanced atherosclerotic lesions (Björnheden 
1999, Sluimer 2008, Naghavi 2002).  
2. EXTRACELLULAR ACIDIFICATION OF THE INTIMA 
Local areas with low pH have been measured in deeper layers of 
atherosclerotic plaques (Naghavi 2002). Extracellular pH of endarterectomized 
human carotid artery plaques were measured by the following two 
complementary methods: pH electrodes and visualization with pH-sensitive 
fluorescent dyes. Measurements with the electrode could reach superficial 
layers at 200 µm, and showed acidic pH values of 6.8. With the fluorescent 
dyes, tissue sections covering the entire plaque could be visualized, and low pH 
areas were observed in the deep layers of the atherosclerotic plaque samples. 
Many lines of evidence provide support for low pH in the atherosclerotic 
arterial intima and are discussed in more detail in the following chapters.  
2.1 Intimal thickening 
Based on morphological studies on human autopsy specimens, before 
atherosclerosis had developed, the atherosclerosis prone areas in the coronary 
arteries, and in the abdominal aorta, have diffuse intimal thickenings (DIT) 
reaching ~250 µm (Stary 1992, Nakashima 2002, Nakashima 2008). SMCs are 
the major source of extracellular matrix proteoglycans in the deep layer of DIT, 
where atherogenic lipids deposit eccentrically. Following the enrichment of 
proteoglycans and lipid deposition, immune cells infiltrate these regions.  
Extracellular matrix remodeling, together with intra- and extracellular lipid 
accumulations, thicken the intima larger than DIT present in human arteries 
before atherosclerotic lesions develop. Plaque formation, involving increasal in 
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extracellular matrix and lipid-rich deposits, leads to a dramatic increase in the 
intimal thickness, e.g., in carotid plaques, thicknesses of 1500 ± 350 µm have 
been measured (Sluimer 2008) that, in turn, may promote extracellular 
acidification via several mechanisms.  
2.2 Hypoxia 
Because the intimal layer is avascular, the intimal cells depend on diffusion for 
nutrition and oxygen supply. Normally, cells in tissues are within 20-30 µm 
from a capillary, but in thickened atherosclerotic plaques, the cells are pushed 
much further from the capillaries. Thus, since the maximal oxygen diffusion 
distance in tissues is ~100-300 µm (Torres Filho 1994), the intimal thickness 
of, for example advanced carotid plaques, significantly exceeds the oxygen 
diffusion limit (Sluimer 2008). Therefore, the oxygen tension in pathological 
tissues is reduced (hypoxia) to values below 10 mmHg (<1 %), which is 
significantly less compared to healthy tissues, where the oxygen tension is 20-
70 mmHg (2.5-9.0 %) (Lewis 1999). Also, local oxygen consumption in the 
atherosclerotic intima is increased due to the increasing number of recruited 
monocyte-derived macrophages that transform into highly oxygen-consuming 
lipid-loaded foam cells (Murdoch 2005, Björnheden 1987). Hence, the local 
decreased oxygen supply, together with increased oxygen consumption of 
activated cells, leads to hypoxic zones in advanced atherosclerotic lesions 
(Björnheden 1999, Sluimer 2008). Indeed, low oxygen concentrations are 
found in atherosclerotic plaques (>500 µm) at depths exceeding the oxygen 
diffusion distance; furthermore, in particular, macrophage-rich areas in 
advanced plaques have regions of severe hypoxia (Björnheden 1999, Sluimer 
2008, Leppänen 2006). Additionally, despite their location well within the 
oxygen diffusion distance, some subluminal (20-30 µm) foam cells are already 
hypoxic (Sluimer 2008).  
The hypoxic conditions of advanced atherosclerotic lesions play a role in the 
development of atherosclerosis by several mechanisms (Hultén 2009). By 
reducing the β-oxidation of fatty acids and increasing the triglyceride and fatty 
acid biosynthesis, hypoxia increases the accumulation of triglyceride-
containing intracellular lipid droplets in macrophages (Boström 2006). 
Hypoxia also promotes inflammation by enhancing macrophage-induced 
secretion of chemokines that recruit T-cells to plaques (Danielsson 2008). 
Furthermore, hypoxia may induce changes in the composition of extracellular 
matrix. For example, proteoglycans SMCs synthesize under hypoxia differ in 
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their glycosaminoglycan composition (Figueroa 1999). With regard to 
atherosclerotic plaque acidification, under hypoxic conditions macrophages 
switch to anaerobic glycolysis to regenerate ATP, which increases their proton 
release (Levin 2003).  
2.3 Macrophage adaptation to hypoxia generates acidic metabolites 
Intimal cells can adapt to low-oxygen and nutrient supply (Roiniotis 2009). 
This adaptation is seen in concentration gradients of energy metabolites across 
the arterial wall, measured with bioluminescence imaging (Levin 2003, 
Leppänen 2006). Under hypoxic conditions, the energy metabolites of the 
intimal cells, ATP, glucose, glycogen, and lactate, have heterogeneous intimal 
distributions. The majority of ATP production of macrophages under hypoxic 
conditions is created via anaerobic breakdown of glucose, which produces high 
local concentrations of lactate (>10mM), with a pKa value of 3.86. Potentially 
harmful accumulation of lactate is a good indirect marker for tissue hypoxia, 
and may partly explain the decrease in the extracellular intimal pH, because 
increased lactate production coincides with cellular acidosis (Toffaletti 1991).  
The key role of oxygen is to maintain mitochondrial ATP production in cells. 
Hydrolysis of ATP molecule releases one proton, however, under normal 
conditions when the demand of ATP is met by mitochondrial respiration, the 
released protons are used by the mitochondria for oxidative phosphorylation 
and for maintaining the proton gradient in the intermembranous space (Robergs 
2004). However, immune cells, particularly macrophages, efficiently adapt to 
hypoxia by relying on anaerobic glycolysis, which occurs in the cytosol (Levin 
2003, Leppänen 2006). Oxygen independent glycolysis is more energy-
inefficient than mitochondrial ATP production; it consumes 18 times more 
glucose per ATP molecule produced (McConnell 1992). To meet this high 
glucose demand, the HIF-1α-regulated glucose transporter GLUT-3 is 
upregulated in hypoxic macrophages (Sluimer 2008).  
Figure 2 shows, schematically, the main reactions of the cytosolic anaerobic 
glycolysis that immune cells use to convert most of their glucose into lactate in 
order to regenerate ATP (Newsholme 1987). In addition to 2 NADH, the net 
reactions produce 2 protons and 2 ATP, when glucose is converted to 2 
pyruvates, and 1 proton and 3 ATP when glycogen is converted to 2 pyruvates. 
However, NAD+ must be generated in order to maintain glycolysis. Under 
anaerobic conditions, tissues regenerate NAD+ in the cytosol in a lactate 
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dehydrogenase catalyzed reaction, which converts pyruvate to lactate and 
consumes 1 proton per molecule. Therefore, the reaction of lactate production 
functions as a buffer against cellular proton accumulation. There is no net 
production of protons when converting glucose to lactate, and a decrease of 
one proton occurs when converting glycogen to lactate. However, when 
anaerobic glycolysis in the cytosol is coupled with ATP hydrolysis, the net 
reactions of glycolysis and ATP hydrolysis together release protons that cause 
the cellular acidosis (Robergs 2004). Anaerobic glycolysis is by far the most 
acidifying process in terms of protons produced per turnover of an ATP 
molecule. Lactate produced in the cytosol is removed from the cell by a 
monocarboxylate transporter, which also symports protons. As a result, lactates 
and protons leave the cell stoichiometrically. The protons also may cross the 
plasma membrane by a Na+-H+ exchanger and by proton pumps.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic figure of the reactions of anaerobic glycolysis. For 
simplicity, only the reactions where ATP or protons are involved are 
shown. The product of anaerobic glycolysis, lactate, is secreted along with 
the protons produced in the hydrolysis of ATP. 
Additionally, macrophages secrete matrix-destructive lysosomal enzymes with 
an acidic pH optimum (cysteine proteinases) together with protons, which may 
locally acidify the pericellular milieu (Punturieri 2000). The contact of 
17  
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macrophages with LDL aggregates may also promote the formation of acidic 
extracellular compartments at the cell surface of macrophages (Haka 2009). 
The pH of the interstitial fluids of the atherosclerotic lesions will, of course, 
depend not only on the rate of proton release from the macrophages and other 
cells of the lesions, but also on the rate of proton removal from the lesions as 
well as the buffering capacity of the interstitial fluid (Leake 1997). With 
bioluminescence imaging in snap frozen arteries, the energy metabolites of 
arterial wall have been measured at high spatial resolution (Levin 2003). Thus, 
incubation at hypoxia resulted in increased lactate concentrations in the deep 
areas of the intima, whereas ATP, glucose, and glycogen concentrations were 
decreased close to zero. The ATP depletion observed may also result from the 
futile cycle of hydrolysis and re-esterification of cholesteryl esters that 
consumes ATP in lipid-loaded macrophages (Brown 1980). 
2.4 Electrostatic interactions between proteoglycans and protons 
Proteoglycans are large macromolecules that consist of polyanionic sugar 
chains called glycosaminoglycans (GAGs) covalently linked to a core protein. 
The polyanionic nature of GAGs enables electrostatic interactions between 
GAGs and cationic atoms or molecules or positively charged regions of 
macromolecules (Chakrabarti 1980). The net negative charges of GAGs are 
due to negatively charged carboxyl and sulfate groups. These groups are acids, 
the sulfate groups with pKa values below 2, and the carboxyl groups with pKa 
values between 3-5 (Chakrabarti 1980). Because of the electrostatic 
interactions between protons and negatively charged carboxyl and sulfate 
groups of GAGs, the proton concentration very near to GAG chains can be 
high, i.e. the pH is lower than the pH found further away (Maroudas 1988). 
2.5 Acidic products generated by lipoprotein modifications 
The reversible interactions of LDL with human arterial proteoglycans increases 
LDLs susceptibility to in vitro oxidation (Hurt-Camejo 1992). All the major 
cell types present in atherosclerotic lesions are able to oxidize LDL, i.e., 
endothelial cells (Henriksen 1981), SMCs (Henriksen 1983), macrophages 
(Parthasarathy 1986), and lymphocytes (Lamb 1992). Extensive LDL oxidation 
by these cells usually requires a catalyst. In the intima, iron or copper ions, 
nitric oxide or nitrite ions, myeloperoxidase, and lipoxygenase can catalyze the 
lipoprotein oxidation reactions. In plasma, iron and copper are carried in the 
proteins transferrin and caeruloplasmin. Decreasing pH increases LDL 
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oxidation by these proteins and also releases iron from transferrin enabling it to 
catalyze LDL oxidation (Lamb 1994a, Lamb 1994b). Decreasing pH also 
increases the reaction rate of LDL oxidation by iron or iron-cysteine in the 
presence or absence of cells (Morgan 1993, Morgan 1995). Interestingly, 
hypoxic macrophages oxidize LDL to a significantly higher extent than 
normoxic cells; they also express more of the LDL-oxidizing enzyme 15-
lipoxygenase-2 (Rydberg 2004). Thus, LDL is oxidized within atherosclerotic 
lesions, and oxidized LDL (ox-LDL) is involved in several atherogenic 
processes (Berliner 1996, Navab 2004). It has been proposed that localized 
acidic pH found in advanced atherosclerotic lesions can be the underlying 
reason why atherosclerotic lesions are one of the few sites in the body where 
extensive LDL oxidation occurs (Leake 1997). LDL oxidation itself generates 
acids as end-products, conjugated dienes and hydroperoxides, which may 
further acidify the extracellular pH of the arterial intima (Leake 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Acidification of the arterial intima. 
Lipoprotein particles can also undergo phospholipolytic modifications in the 
arterial intima (Jönsson-Rylander 2008, Rosenson 2009a, Karabina 2010, 
Öörni 2009). Phosphatidylcholine (PC) is the main phospholipid component of 
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the monolayer covering lipoprotein particles. Its hydrolysis by the PLA2 
enzyme generates lysophosphatidylcholine (lysoPC) and free fatty acid (FFA) 
as end products. Also upon oxidation, the lysoPC content of LDL increases 
dramatically, compared to only 1–5 % lysoPC of the total PC content of native 
LDL (Chen 1997). This increase in lysoPC content can be the result of two 
sequential events: oxidation of the sn-2 chain of PC (ox-PC), followed by 
oxidized sn-2 fatty acid hydrolysis by lipoprotein-associated PLA2 (Lp-PLA2) 
or secretory phospholipase A2 group X (sPLA2-X), generating lysoPCs, and 
oxidized free fatty acids (ox-FFAs). Additionally, the acetyl moiety at the sn-2 
position of platelet-activating factor (PAF) can be hydrolyzed, releasing acetate 
along with the lyso-platelet-activating factor (lysoPAF) (Stafforini 2009, 
Karabina 2010). Thus, sPLA2 enzymes may hydrolyze PCs or ox-PCs (van 
Kuijk 1987, Matsumoto 2007), and release a wide spectrum of acidifying 
products to the intima, including hydroperoxides, acetate, lysophospholipids, 
FFAs, and ox-FFAs.  
3. ATHEROGENIC APOB-100-CONTAINING 
LIPOPROTEIN PARTICLES  
Lipoprotein particles are divided into classes differing in their density. This 
classification is primarily determined by protein and triglyceride contents 
where the less dense particles have a high triglyceride content and the more 
dense particles have a high protein content (Hilbert 2007). Cholesterol in 
plasma is carried by several lipoprotein particle classes that transport dietary 
and endogenously produced lipids. The four lipoprotein classes that carry 
endogenously produced lipids are: high-density lipoprotein (HDL), LDL, IDL, 
and VLDL, in the order of increasing particle diameter and triglyceride content 
(see Table 1.). In the postprandial state, dietary lipids are carried in 
chylomicrons and chylomicron remnants. 
The apoB-100-containing lipoprotein particles are secreted into the circulatory 
system from the liver as large triglyceride-rich VLDL particles, which 
transport fatty acids to adipose tissue and muscle. In the circulation, VLDL 
particles are transformed, through the action of lipases and plasma lipid 
transfer proteins, into smaller cholesteryl ester-rich LDL particles. LDL 
particles are the principal plasma cholesterol carriers and serve as a source of 
cholesterol for most tissues of the body through receptor-mediated recognition 
of apoB-100 (Brown 1986). As a consequence of intravascular VLDL 
metabolism, the circulating apoB-100-containing lipoprotein particles are 
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heterogeneous in size, density, surface charge, lipid, and apolipoprotein 
compositions. 
3.1 Lipoprotein particle structure 
The structure of lipoprotein particles enables the water-solubility and transport 
of insoluble lipids in blood. Hydrophobic triglycerides and cholesteryl esters 
are located in the particle core and are solubilized by a surface monolayer of 
phospholipids, sphingolipids, and cholesterol. These particles are stabilized by 
proteins (Prassl 2009). Importantly, the so called apoB-100-containing 
lipoproteins, i.e. VLDL, IDL, and LDL, are considered atherogenic, and each 
particle contains a single molecule of non-exchangeable apoB-100 located at 
the particle surface. ApoB-100 is one of the largest single polypeptide chains 
known, containing 4536 amino acids (MW=513 000) (Yang 1986, Knott 
1986). It is synthesized by the liver and together with apoE secreted on VLDL 
particles. After triglyceride removal in peripheral tissues, the remaining VLDL 
remnants are metabolized to LDL particles by further removal of the core 
triglycerides and the dissociation of apolipoproteins, other than the apoB-100. 
Hence, hydrolysis of VLDL results in IDL particles, and finally LDL particles.  
Due to the size and hydrophobic nature of apoB-100, its structure, when 
associated with lipoprotein particles, is not well characterized (Johs 2006, 
Segrest 2001, Prassl 2009). ApoB-100 is located at the surface of lipoprotein 
particles, and its amphipathic α-helices and β-sheets represent the major lipid-
associating motifs. The β-sheets are believed to penetrate more deeply into the 
particles and directly contact the neutral lipids of the core, playing a role in the 
organization of core lipids. Interestingly, the surface pressure of a lipoprotein 
particle decreases with decreasing particle size, and, with decreasing 
lipoprotein particle size, an increasing number of amphipathic helices of apoB-
100 are associated with the surface lipids that modulate these surface pressure 
decreases (Segrest 2001). 
In addition to apoB-100, lipoprotein particles also contain other smaller 
apolipoproteins that are divided into the following alphabetical classes: apo-A, 
B, C, D, E, etc. These are attached to lipoproteins through amphipathic helices 
that intercalate into the phospholipid monolayer and have various functions, 
including lipid transport in blood, enzyme regulation involved in lipid 
metabolism, and lipoprotein binding to receptors. The membrane association of 
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these small apoliproteins is sensitive to the surface pressure of the particles 
(McNamara 1996). 
Table 1. Composition of the lipoproteins in human plasma* 
  
HDL LDL IDL VLDL 
Chylo- 
microns 
 Particle size 
(nm) 5 –12 18 – 30 25 – 35 30 – 80 75 – 1200 
 Density 
(g/ml) 
1.063 – 
1.210 
1.019 – 
1.063 
1.006 – 
1.019 
0.95 – 
1.006 < 0.95 
Cholesteryl 
esters 
(% dry weight) 
10 – 20 35 – 50 22 10 – 22 2 - 5 
Core 
lipids 
Triglycerides 
(% dry weight) 2 – 7 4 - 10 20 - 30 45 - 65 80 – 95 
Cholesterol 
(% dry weight) 
3 - 5 6 - 10 7 – 10 4 - 10 1 – 3 
Phospholipids 
(% dry weight) 
20 - 35 15 – 24 20 15 - 20 3 – 9 
Proteins 
(% dry weight) 40 - 55 18 - 25 15 - 20 5 - 10 1 - 2 
Surface 
lipids 
and 
proteins 
Major 
apolipoproteins 
A-I,II,IV; 
C-I,II,III; 
D; E 
B-100 
B-100; C-
I,II,III; 
E 
B-100; C-
I,II,III;E 
A-I,II,IV; 
B-48; C-
I,II,III; E 
 * Values are taken from: (Hilbert 2007)  
3.2 Lipoprotein particles entering the intima 
Size is the major restricting factor affecting lipoprotein particles’ ability to 
enter the arterial intima. Chylomicrons, chylomicron remnants, and large 
VLDL particles are primarily excluded from the intima. The particles that are 
able to enter the arterial intima are <75 nm. These also include the small VLDL 
(sVLDL) particles (Nordestgaard 1995). The triglyceride-rich IDL and sVLDL 
particles are larger than LDL particles, and have a slower rate of efflux from 
the arteries than LDL-sized particles (Proctor 2004). The plasma 
concentrations of IDL and sVLDL increase in familial combined 
hyperlipidemia, type III hyperlipidemia, chronic renal failure, and non–insulin-
dependent diabetes mellitus. In these conditions, the triglyceride-rich 
lipoprotein particles are considered at least as atherogenic as LDL particles 
(Nordestgaard 1995). Also, a study in rabbits has demonstrated that IDL 
cholesterol, and IDL plus sVLDL cholesterol, are a better predictor of the 
extent of atherosclerosis than is LDL cholesterol (Nordestgaard 1991). 
Furthermore, results from some epidemiological studies have shown that 
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elevated triglyceride-levels increase the risk of coronary heart disease 
independent of LDL cholesterol levels, and an elevated level of IDL 
cholesterol has been suggested to be an independent risk factor for the 
development of atherosclerosis (Stalenhoef 2008, Niemi 2009). 
Once the lipoprotein particles have entered the arterial intima, they can interact 
with the components of the extracellular matrix. The entrapment of lipoprotein 
particles in the extracellular matrix prolongs their residence time in the intima 
and predisposes them to modifications by enzymes and agents secreted by 
intimal cells (Pentikäinen 1997). Using immunohistochemical stainings, 
enzymatically modified lipoprotein particles have also been detected in the 
arterial intima (Torzewski 1998), and the extracellular lipid droplets that have 
aggregated and fused, possess qualities suggesting that they are derived from 
modified plasma LDL particles (Öörni 2000). Thus, lipids derived from plasma 
lipoproteins accumulate in the intima in the form of lipid droplets. The 
extracellular lipid droplets may be derived from apoB-100-containing 
lipoprotein particles or from dying foam cells. Lipid analysis of extracellular 
perifibrous lipid droplets in the lipid core has revealed that their cholesterol is 
mainly esterified with linoleate, as is also found in the core of circulating 
apoB-100-containing particles, whereas the intracellular lipid droplets in foam 
cells contain cholesterol esterified with oleate (Deckelbaum 1977, Smith 
1974). Furthermore, electron microscopic pictures of the rather small diameters 
(40-200 nm) of the extracellular lipid droplets support the notion that the 
extracellular lipid droplets originate directly from lipoprotein particles rather 
than from the cytoplasmic lipid droplets of foam cells, which have much larger 
lipid droplet diameters (300-6000 nm) (Chao 1990). 
4. MODIFICATION OF LIPOPROTEINS BY 
PHOSPHOLIPASE A2 
PLA2 enzymes have important roles in diverse physiological processes that 
involve the turnover of membrane phospholipids. These include the digestion 
of foreign agents, such as bacteria and viruses, and the release of arachidonic 
acid for eicosanoid synthesis. The superfamily of PLA2 enzymes include 
secretory, cytosolic, calcium-independent, and lysosomal forms, as well as the 
platelet-activating factor acetylhydrolase (PAF-AH) (Burke 2009, Murakami 
2002). All PLA2 enzymes act on the sn-2 position of phospholipids to liberate 
FFAs and lysophospholipids. PLA2 enzymes have been proposed to generate 
high levels of hydrolysis products at highly localized nanodomains of 
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membranes, thereby directly affecting local membrane curvature (Brown 
2003). The localized enzymatic action of PLA2 in a phospholipid membrane 
can be understood by its scooting mode in which the enzyme binds to a 
membrane and catalyzes the hydrolysis of even hundreds of phospholipids 
without leaving the membrane (Berg 2001, Jain 2006). 
The secretory PLA2 (sPLA2) and Lp-PLA2 families are of interest regarding the 
hydrolysis of PC, the major phospholipid of lipoprotein particles. These 
hydrolyze the sn-2 chains of PC and generate both lysoPCs and FFAs (Öörni 
2009, Wilensky 2009). The PCs and phosphatidylethanolamines (PE) in 
lipoproteins may also contain an ether-linked sn-1 alkyl chain, and Lp-PLA2 or 
sPLA2 acting on these lipids produces lysoPE, lysoPAF and FFA (Snyder 
2002). Prior to their lipolytic modification, lipoprotein particles may also 
become oxidized (Matsumoto 2007). In the oxidation of phospholipids, 
radicals attack the unsaturated fatty acids in LDL particles, notably the sn-2 
chains of phospholipids, and this lipid peroxidation leads to formation of 
hydroperoxides and release of aldehyde fragments (malondialdehyde; MDA 
and 4-hydroxynonenal; 4-HNE). Indeed, circulating LDL, despite the potent 
antioxidant capacity of plasma, has been shown to contain oxidized 
phospholipids (Ishigaki 2009), and the oxidation of lipoprotein particles has 
been shown to play an important role in atherogenesis (Navab 2004, Ishigaki 
2009).  
4.1 Secretory phospholipase A2 
The family of sPLA2 enzymes generally have high numbers of disulfide bonds 
(6-8 bridges), and low molecular masses (13-18 kDa), with the exception of the 
notably large size of sPLA2-III (~55 kDa) (Lambeau 2008, Valentin 2000, 
Boyanovsky 2009b, Rosenson 2009a). The sPLA2 enzymes differ in their 
substrate specificity with respect to the polar headgroup size and the acyl chain 
composition and type of linkage (Gesquiere 2002, Chen 1998, Winget 2006). 
An interesting property of sPLA2 enzymes (except sPLA2-III) is their 
interfacial activation (Jain 2006). The surface of the enzyme that contacts the 
phospholipid surface is called interfacial binding surface (i-face). The 
interaction between the i-face and the aggregate substrate may control access to 
the substrate. Indeed, when bound to the phospholipid monolayer or bilayer of 
the aggregate substrate, the observed rate of hydrolysis of sPLA2 is more than 
1000 times greater than with monodisperse phospholipids (Jain 2006). Thus, 
the ability of sPLA2 to bind to the phospholipid membrane is crucial for its 
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activity. The binding of sPLA2 to phospholipid membrane is sensitive to the 
phospholipid chain melting phase transition region, which depends on pH, 
ions, membrane potential, proteins, and changes in hydration (Kinnunen 1991). 
However, despite growing knowledge on interfacial enzymes, and especially 
sPLA2, the biophysical steps involved in interfacial recognition and adsorption 
are still only partially understood (Winget 2006). Also the efflux propensity of 
phospholipid substrate is an important factor in the hydrolysis of phospholipid 
molecules by several PLA2 enzymes (Haimi 2010).  
4.2 Secretory phospholipase A2 enzymes in atherosclerosis 
A number of studies have shown that elevated activity and plasma 
concentrations of PLA2 enzymes increase the risk of cardiovascular events 
(Koenig 2006, Brilakis 2005, Kugiyama 1999, Liu 2003, Kugiyama 2000, 
Mallat 2007, Koenig 2009). The activity of PLA2 enzymes present in the blood 
plasma have been shown to be increased by acidity and plasma dilution 
(Costello 1990). Since the intimal fluids are an ultrafiltrate of blood plasma and 
the plasma-derived proteins contained in it are diluted (Smith 1990), it is 
conceivable that in the intimal fluids the activity of PLA2 enzymes is increased. 
In the arterial intima, out of the ten known mammalian sPLA2 enzymes, seven 
have been shown to have various patterns of distribution and production at all 
stages of atherosclerotic lesion development (Kimura-Matsumoto 2008). Also, 
Lp-PLA2 has been shown in advanced atherosclerotic plaques, associated with 
apoptotic macrophages (Häkkinen 1999, Kolodgie 2006). Furthermore, the 
compositional analysis of lipoproteins isolated from human atherosclerotic 
arteries show decreased PC content, supporting the role of PLA2 enzymes in 
the modification of lipoprotein particles (Camejo 1985, Tailleux 1993). 
Currently, of the sPLA2 family members, the groups sPLA2-IIA, sPLA2-III, 
sPLA2-V, sPLA2-X, and also the Lp-PLA2, are regarded as promoters of lipid 
accumulation in the arterial intima (Menschikowski 1995, Sato 2008, Wooton-
Kee 2004, Curfs 2008). These enzymes have different lipolytic activities and 
substrate specificities, and thus have been suggested to play different roles in 
the development of atherosclerosis (Rosengren 2006a, Öörni 2009, Jönsson-
Rylander 2008).  
Extensive PLA2 hydrolysis of lipoprotein particles may increase their 
atherogenicity by several routes: provoking their aggregation and fusion (Hurt-
Camejo 2001a, Öörni 2005), increasing their binding to extracellular matrix 
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proteoglycans (Sartipy 1999, Öörni 1998), and increasing their uptake by 
macrophages (Menschikowski 1995, Boyanovsky 2005).  
4.3 Role of secretory phospholipase A2 group V in atherosclerosis 
Recently it was shown in mouse models that a hyperlipidemic high-fat diet 
upregulates the expression of sPLA2-V in the aorta (Rosengren 2006b). Also, 
by immunohistochemical stainings, it was shown that sPLA2-V is present in 
human and mouse atherosclerotic lesions, and that the enzyme is associated 
with SMCs and foam cells in lipid core areas of the atherosclerotic plaques 
(Wooton-Kee 2004, Rosengren 2006b, Kimura-Matsumoto 2008). Importantly, 
sPLA2-V enzyme was shown to have a role in the development of 
atherosclerosis in LDL receptor-deficient mice (Boström 2007). Thus, the 
expression of sPLA2-V in bone marrow-derived cells increased atherosclerotic 
lesion area by 2.7-fold, while deficiency of the enzyme reduced atherosclerotic 
lesion area by 36 %. The plasma sPLA2-V activity of the mice did not change, 
which further supports the idea that increased lipid deposition in the mice 
overexpressing sPLA2-V was attributable to the lipolytic activity of this 
enzyme within the arterial intima.  
sPLA2-V shows high enzymatic activity toward lipoprotein phospholipids in 
human plasma (Rosengren 2006b). Lipolysis of LDL by sPLA2–V reduces the 
LDL particle size and increases particle density (Wooton-Kee 2004). The small 
dense LDL particles are considered more atherogenic since they exhibit 
enhanced binding to extracellular matrix and cell-surface proteoglycans than 
normal-sized LDL particles (Sartipy 1999, Hurt-Camejo 2001b). Modification 
of LDL by sPLA2-V can also contribute to intracellular lipid accumulation and 
to the formation of macrophage foam cells (Wooton-Kee 2004, Boyanovsky 
2005, Boyanovsky 2009a). Interestingly, nuclear factor κB (NFκB), a 
transcription factor and a key regulator of inflammation that has been 
implicated in atherosclerotic processes (de Winther 2005), is translocated to the 
nucleus after macrophages have been incubated with the lipolytic products 
released from sPLA2-V-modified LDL particles (Boyanovsky 2010). 
Consequently, incubation of macrophages with sPLA2-V-modified LDL 
increases the expression of NFκB target genes, such as pro-inflammatory 
cytokines TNF-α and IL-6 (Boyanovsky 2010).  
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4.4 Release of bioactive lysophospholipids and free fatty acids 
Several lipolytic and proteolytic enzymes are highly induced in the 
atherosclerotic arterial intima and lipoprotein particles are prone to extensive 
modifications. However, it is currently not known which specific enzymes of 
the human arterial intima are actually responsible for turning the intimal 
lipoproteins into atherogenic particles. Some of the lipolytic enzymes 
potentially involved in such atherogenic conversion of lipoproteins include: 
phospholipases (Öörni 2009), cholesteryl ester hydrolases (Suriyaphol 2002), 
lipoprotein lipase (Mattsson 1993, Ichikawa 2005, Pentikäinen 2002), and 
lysosomal acid lipase (Hakala 2003). Simultaneous action of the various 
enzymes that hydrolyze cholesteryl esters and phospholipids may generate vast 
amounts of lipolytic products from lipoprotein particles. The lipolytic products 
formed by the action of PLA2, lysophospholipids and free fatty acids, are 
highly bioactive molecules, and they play a role in the atherogenicity of the 
lipolytically modified lipoproteins (Hurt-Camejo 2001a, Öörni 2009, 
Matsumoto 2007, Schmitz 2009).  
FFAs have effects on several cell-types found in the arterial intima. FFAs 
induce adhesion molecule expression and secretion of various cytokines in 
endothelial cells, and they increase cholesterol uptake and reduce cholesterol 
efflux from macrophages (Suriyaphol 2002, Oram 2004). Overexposure of 
arterial SMCs to FFAs also augments production of matrix proteoglycans with 
increased size and LDL shows an increased affinity for these altered 
proteoglycans (Olsson 1999, Rodriguez-Lee 2007). More severely, human 
vascular endothelial cells and human SMCs incubated with high FFA-plasma, 
or a mixture of FFAs, become apoptotic (Oram 2004, Artwohl 2004, Artwohl 
2009). FFAs can also induce apoptosis in macrophages, but only when carried 
in lipoprotein particles (Chung 1995).  
LysoPC has direct proinflammatory and atherogenic effects on almost all cell-
types present in atherosclerotic lesions, including: SMCs, T-cells, monocytes, 
macrophages, platelets, endothelial cells, and neutrophils (Matsumoto 2007, 
Schmitz 2009). With regard to monocytes, lysoPC acts as a chemoattractant 
that plays a role in the recruitment of more monocytes into the arterial intima 
(Quinn 1988); it also stimulates interleukin-1 beta (IL-1β) production by 
monocytes (Liu-Wu 1998). Thus, in atherosclerosis, lysoPC acts as an 
atherogenic lipid mediator between modified lipoprotein particles and the 
arterial cells. The effects of lysoPC can be partly explained by its chemical 
Literature Review 
28  
properties (reviewed by Matsumoto 2007), comprised of a long hydrophobic 
fatty acyl chain and a large hydrophilic headgroup. This amphipathic nature 
gives lysoPC surfactant- and detergent-like properties. At low concentrations, 
lysoPC exists as single molecules in solution, which can readily insert into the 
outer layer of the cell membrane, but do not appear to flip into the inner layer. 
After exceeding its critical micellar concentration in solution, lysoPC forms 
small micelles with detergent-like properties. The small micelles may fuse with 
cell membranes and disturb membrane conformation, and even lyse cells. 
Importantly, the apoptotic cell death is initiated by the secretion of lysoPC that 
plays a role as an “eat-me” signal, inducing the recruitment of phagocytes 
(Lauber 2003). The lysoPCs of the modified lipoprotein particles may also 
induce a similar effect. The accumulation of lysoPC in lipoprotein particles 
reflects either its increased production via PLA2 enzyme activity or its 
decreased catabolism via enzymatic reacylation (Matsumoto 2007). Thus, 
scavenger receptor expression on the surface of macrophages is upregulated by 
lysoPC (Kita 2000), and ox-LDL particles containing high amounts of lysoPC 
are avidly internalized.  
5. EXTRACELLULAR RETENTION OF LIPOPROTEIN 
PARTICLES 
The key initiating event in early atherosclerosis is the subendothelial retention 
of cholesterol-rich, atherogenic lipoproteins, which, once retained, provoke a 
cascade of responses that lead to disease in a previously non-lesional artery. 
This so-called response-to-retention hypothesis is regarded as a central 
paradigm in our understanding of the pathogenesis of atherosclerosis (Williams 
1995, Williams 1998, Tabas 2007).  
As discussed earlier, atherosclerotic lesions tend to develop in specific areas of 
arteries, the DITs, suggesting that there are some local factors promoting 
atherogenesis in these atherosclerosis-prone zones (Nakashima 2008). It 
appears that the higher lipoprotein concentration in atherosclerosis-prone areas 
mainly depends on selective lipoprotein retention and degradation (Schwenke 
1989). After entering the arterial intima from the circulatory system, 
lipoprotein particles may become entrapped within the dense extracellular 
matrix network of the intima, and bind to the matrix components, especially to 
proteoglycans (Skålen 2002, Wight 2004).  
Literature Review 
5.1 Extracellular matrix proteoglycans 
Proteoglycans provide elasticity and volume to the arterial wall, and are mainly 
produced and secreted by SMCs (Olsson 1999). In the structure of 
proteoglycans, GAG chains are covalently attached to a core glycoprotein. The 
GAG chains are linear, highly polyanionic polymers of repeating disaccharides 
(Chakrabarti 1980). Because of their high anionic charges, they bind 
electrolytes and water in extracellular fluids and form a hydrated gel that 
mediates mechanical strength and support of tissues.  
The relative amount, molecular size, and type of GAGs are tissue-specific, and 
the proteoglycans may be classified by their predominant GAGs. The 
proteoglycan-rich intimal layer of the arterial wall is mainly composed of 
proteoglycans known as versican, biglycan and decorin (see Figure 4.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structures of arterial wall proteoglycans versican, biglycan, and 
decorin.  
Versicans have up to 23 chondroitin sulfate GAG chains attached to a core 
protein with four alternative sizes (V0-V3, 370-72 kDa) (Zimmermann 1989, 
Wight 2004). Also present are smaller proteoglycans known as biglycan and 
decorin, which have 1-2 chondroitin sulfate or dermatan sulfate GAG chains 
29  
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attached to a ~40 kDa core protein (Cardoso 1994). Versican forms aggregates 
with hyaluronan, which is composed of a very long GAG chain. The 
hyaluronan-versican aggregates form enormous and tight proteoglycan 
networks within the extracellular matrix (Wight 2002).  
Interestingly, proteoglycans in atherosclerosis-prone areas of the arteries have a 
higher binding affinity toward LDL than proteoglycans originating from low 
risk areas (Cardoso 1994). As the atherosclerotic lesions progress, the 
proteoglycan composition of the extracellular matrix changes; specifically, the 
chondroitin sulfate chains undergo structural changes that promote lipoprotein 
retention (Wagner 1986, Cardoso 1994).  
The major changes to the extracellular matrix composition are made by SMCs, 
which migrate to the intimal layer from the media. After proliferation, SMCs 
secrete increased amounts of proteoglycans having a high affinity for LDL 
(Tao 1997, Doran 2008). Oxidation and hydrolysis of lipoprotein particles 
generates FFAs and lysoPCs, which play important roles in these processes, as 
discussed in section 4.4. LysoPC is one of the factors that increases the 
proliferation and migration of SMCs (Kohno 1998), and FFAs induce arterial 
SMCs to synthesize proteoglycans with increased affinity toward LDL (Olsson 
1999, Rodriguez-Lee 2007).  
5.2 Lipoprotein entrapment in the extracellular matrix 
Lipoproteins directly bind to proteoglycans via electrostatic interactions 
between the negatively charged glycosaminoglycan side chains of 
proteoglycans and the positively charged residues, arginine and lysine, of 
apolipoproteins (Iverius 1972). In human apoB-100, site B (residues 3359-
3369) is the functional proteoglycan-binding site (Borén 1998); however site A 
(residues 3148–3158) can also act co-operatively with site B. Site A is able to 
bind to proteoglycans after LDL particles have been lipolyzed by sPLA2, which 
induces a conformational change in apoB-100 (Flood 2004). Indeed, sPLA2-
lipolysis increases lipoprotein binding to proteoglycans (Sartipy 1999, Öörni 
1998). Interestingly, the association of sPLA2-V enzyme with proteoglycans 
enhances its hydrolytic activity toward lipoproteins (Rosengren 2006b). 
5.3 Lipoprotein aggregation and fusion  
The outer monolayer of lipoprotein particles is mainly composed of 
phospholipids (Dowhan 2002), and a growing interest is the need to understand 
the biophysical properties of the monolayer lipids that may directly affect the 
Literature Review 
31  
aggregation and fusion events of lipoprotein particles (Burger 2000), and the 
functions of various lipoprotein particle associated proteins (Phillips 2009). 
Indeed, lipids appear to play a key role in the fusion behavior of lipoprotein 
particles (Chernomordik 2008, Zellmer 1994, Knecht 2007). Fusion of 
lipoprotein particles requires strong membrane bending and highly curved non-
bilayer lipid intermediates (Chernomordik 2008, Chernomordik 2003, Burger 
2000), which are proposed to include phospholipids and lysophospholipids 
(Kooijman 2005, Kooijman 2003). The process of membrane bending depends 
on spontaneous curvature, which is influenced by external factors such as pH, 
temperature, and salt concentration. Both low pH and divalent cations can 
induce headgroup dehydration, and thus reduce the effective headgroup size by 
neutralizing the negatively charged headgroup regions. Reducing the 
headgroup size causes negative direction to monolayer curvature, which is an 
important parameter involved in membrane fusion (Chernomordik 2008). 
Additionally, the changes in atomic charges and molecular shapes of the 
membrane lipids (Kooijman 2003) may induce negative membrane curvature, 
and these may be altered in vivo by lipolytic enzymes or by oxidation.  
Lipolytic, proteolytic, and oxidative modifications disrupt the surface of LDL 
particles and induce their fusion in vitro, which suggest that these 
modifications may also induce LDL fusion in the arterial intima. In vitro, 
proteolysis by α-chymotrypsin, trypsin, pronase, or cathepsins F, K, and S 
leads to fragmentation of apoB-100 and to fragment release from the LDL 
particle surface, and, importantly, the loss of protein fragments triggers the 
fusion of the particles (Piha 1995, Öörni 2004). Oxidation by copper-ions, and 
lipolysis by sphingomyelinase, produces lipid droplets of similar appearance to 
those found in the initial atherosclerotic lesions of the arterial intima 
(Pentikäinen 1996, Öörni 1998). Particle fusion may also occur when the 
lipoprotein particles are bound to the extracellular matrix of the arterial intima 
(Pentikäinen 1996). In fact, when bound to the human arterial proteoglycans, 
the rate of proteolytic LDL fusion is increased (Pentikäinen 1997). The PLA2-
modified lipoprotein particles have been shown only to aggregate (Öörni 1998, 
Wooton-Kee 2004), but they fuse when heparin-treated or heparin-bound 
(Hakala 1999).  
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6. INTRACELLULAR ACCUMULATION OF 
LIPOPROTEIN PARTICLES  
Macrophages are the most abundant type of inflammatory cells in 
atherosclerotic lesions (~80% of lesional leukocytes), and they are present in 
lesions at all stages of atherosclerosis (Gerszten 2000). Macrophages are 
derived from blood monocytes, which, after circulating for several days, 
migrate into tissues where they differentiate into various tissue macrophages or 
dendritic cells. The outcome of the differentiation process into tissue 
macrophages depends on inherent properties of different monocyte populations 
as well as environmental factors in the tissue (Gordon 2005), leading to several 
macrophage phenotypes being present in atherosclerotic lesions (Johnson 2009, 
Mantovani 2009). There are two primary cytokines that promote monocyte 
differentiation into the macrophage phenotype: monocyte colony-stimulating 
factor (M-CSF) and granulocyte-macrophage colony-stimulating factor (GM-
CSF) (Barreda 2004). Macrophages differentiated with M-CSF are 
CD68+/CD14+, and represent the macrophage phenotype that predominates the 
diseased arterial intima (Waldo 2008). Already at the early stages of 
atherosclerosis, arterial macrophages take up lipoproteins by an unregulated 
mechanism, leading to intracellular lipid droplet accumulation (Stary 2000).  
Macrophages have different kinds of cell-surface proteins and proteoglycans 
capable of binding and internalizing native, aggregated or modified lipoprotein 
particles. At least four major lipoprotein receptor types have been characterized 
that could be involved in arterial lipid uptake: 1) LDL receptor (LDLR), 2) 
LDL receptor-related protein 1 receptor (LRP-1), 3) VLDL receptor, and 4) 
scavenger receptors (SRs). Importantly, differentiated macrophages express 
LDLR poorly, but all the other receptor types are expressed abundantly in 
macrophages in atherosclerotic lesions, suggesting that no single receptor 
pathway is alone responsible for the uptake and degradation of lipoproteins by 
macrophages (Hiltunen 1998). Additionally, it has been suggested that arterial 
macrophages may have cell-surface receptors with an acidic pH-optimum for 
the binding of lipoprotein ligands (Ling 2004, Basu 1978). However, the 
function and characteristics of these cell-surface receptor proteins that have 
acidic pH-optimum are still poorly understood. 
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6.1 Receptor-mediated uptake 
The uptake of native LDL particles to the cells is mainly by the LDLR, but 
differentiated macrophages express LDLRs poorly. LDLR binding to native 
LDL particles at neutral pH induces the formation of clathrin-coated endocytic 
vesicles. The vesicles quickly lose their clathrin-coating near the cell-surface 
and fuse with the endosome. During endosome maturation, acidic pH inside the 
vesicle induces the release of LDLR from its ligand. The receptor is then 
recycled to the cell-surface, whereas the late endosomes are fused to lysosomes 
(Brown 1986). LDLR is quickly downregulated in response to the entry of 
cholesterol into the cell, and so the LDLR pathway doesn’t lead to excess 
intracellular cholesterol accumulation (Brown 1986). However, the LDLR has 
been proposed to be involved in the phagocytosis of large LDL self-aggregates, 
made in vitro by briefly vortexing LDL or by incubating LDL with 
phospholipase C enzyme (Khoo 1988, Suits 1989), and their uptake by the 
LDLR pathway may lead to formation of foam cells. 
LRP-1, another receptor that belongs to the family of LDLRs (also known as 
α2-macroglobulin receptor and CD 91). It is a very large (600kDa) 
multifunctional plasma membrane protein consisting of 4544 amino acids that 
structurally resembles four combined LDLR molecules (Herz 2001). LRP-1 is 
Ca2+-dependent, like LDLR, and also has a neutral pH optimum for ligand 
binding (Moestrup 1990). The expression of LRP-1 is upregulated in vivo in 
both macrophages and SMCs in human atherosclerotic lesions (Lupu 1994). 
LRP-1 mediates, at least partially, the uptake of matrix-retained 
sphingomyelinase-aggregated LDL to macrophages in the presence of 
lipoprotein lipase (Sakr 2001). LRP-1 has also been shown to have a key role 
in the uptake of aggregated LDL by SMCs (Llorente-Cortes 2000, Llorente-
Cortes 2002a), and LDL particles upregulate the expression of LRP-1 in SMCs 
(Llorente-Cortes 2002b).  
The preponderance of modified LDL particles is taken up via a family of 
macrophage transmembrane proteins referred to as SRs (Goldstein 1979), 
which are divided to subclasses SR A-H (Moore 2006). SRs are able to bind 
bacterial pathogens, apoptotic cells, and modified endogenous proteins such as 
modified lipoprotein particles (Greaves 2009). The mature macrophages 
express SR-AI, SR-AII, SR-BI, and SR-BIII (also known as CD36), which are 
capable of binding modified LDL particles. SRs may be beneficial in the initial 
stages of atherosclerosis as they scavenge the modified lipoprotein particles, 
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but the unregulated nature of SRs activity that results in foam cell formation 
promotes atherosclerosis and chronic inflammation (Moore 2006). Oxidized 
phosphatidylcholines (ox-PCs) are one ligand that SRs recognizes on the 
surfaces of oxidatively damaged or apoptotic cells or ox-LDL (Hörkkö 2000, 
Boullier 2001). Macrophages recognize the ox-PCs and consequently take up 
the ox-LDL particles by SR-AI, SR-AII, and SR-BIII receptors (Podrez 2003, 
Suzuki 1997, Kunjathoor 2002). The binding of ox-LDL particles to SRs 
induces the formation of clathrin-coated endocytic vesicles, where ox-LDL 
particles are degraded in a way that is analogous to LDL in LDLR-induced 
endocytic vesicles (Brown 1986).  
Another lipoprotein binding receptor expressed on the cell-surface of 
macrophages in atherosclerotic lesions is the VLDL receptor (Multhaupt 1996, 
Hiltunen 1998). This 846 amino acid peripheral remnant lipoprotein receptor 
belongs to the LDLR family (Takahashi 2004). It binds apoE-containing 
ligands but not LDL (Gianturco 1982, Van Lenten 1985, Kosaka 2001). Thus, 
the apoE-containing lipoprotein particles VLDL, IDL (VLDL remnants), 
chylomicron remnants, and Lp(a) bind to the VLDL receptor. The expression 
of the receptor and the internalization of ligands is unregulated, leading to the 
formation of foam cells (Takahashi 2004).  
6.2 Receptor-independent uptake 
Macrophages may also internalize lipoproteins through receptor-independent 
mechanisms. The activated human monocyte-derived macrophages, 
differentiated in the presence of human serum, internalize large amounts of 
native LDL through actin-dependent macropinocytosis of extracellular fluid 
(Kruth 2002, Kruth 2005). The same uptake mechanism is also observed, 
without cell activation, in macrophages differentiated in the presence of 10% 
fetal bovine serum containing M-CSF and IL-10 (Zhao 2006). Because the 
macropinocytotic uptake is not downregulated by the incoming cholesterol it 
leads to the formation of foam cells (Kruth 2002, Zhao 2006).  
The uptake of sPLA2-V-lipolyzed LDL particles also occurs through a 
receptor-independent mechanism that depends on cell-surface proteoglycans 
(Boyanovsky 2005, Boyanovsky 2009a). The role of syndecan-4 has been 
especially recognized in the uptake of sPLA2-V-lipolyzed lipoprotein particles. 
Syndecans are cell-surface proteoglycans that contain glycosaminoglycan side 
chains composed of heparan sulfate and chondroitin sulfate (Wegrowski 2006). 
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Another, at least partly receptor-independent mechanism of LDL uptake is the 
phagocytosis of large LDL aggregates (Khoo 1988, Zhang 1997). Interestingly, 
PLA2-lipolysis of LDL also promotes lipoprotein particle aggregation (Öörni 
2005, Öörni 1998).  
6.3 Intracellular lipid storage and degradation by macrophages 
Normally, uptake of lipoproteins by cells results in the complete hydrolysis and 
degradation of their protein and lipid components by lysosomal enzymes 
having an acidic pH-optimum, such as cathepsins and lysosomal acid lipase 
found in the acidic environment of lysosomes. The lysosomal enzymes degrade 
apolipoproteins, and the degraded protein fragments are released into the 
cytoplasm and secreted from the cells (Brown 1986). The lysosomal enzymes 
also hydrolyze the cholesteryl esters of lipoprotein particles, and cholesterol is 
released into the cytoplasm. The cytoplasmic metabolically active pool of 
cholesterol is transported either to cell membranes, or directly to the 
endoplasmic reticulum. However, excessive uptake of lipoprotein particles can 
lead to accumulation of cholesterol in either the lysosomes or in different 
cellular membranes. In particular, in vascular cells, which are highly active in 
the uptake of ox-LDL, cholesterol accumulates in the lysosomes. The ox-LDL 
particles are poorly degraded in the lysosomes, possibly because of the 
resistance of ox-LDL to enzymatic hydrolysis, or because the reactive ox-LDL-
associated moieties can inactivate lysosomal enzymes (Carr 2001). 
The plasma membrane contains most of the total cellular cholesterol. However, 
if the cholesterol/phospholipid ratio of plasma membrane is too high, it can 
inhibit the function of some cholesterol efflux proteins as well as the function 
of other membrane proteins (Cantor 1999, Feng 2002). Excess cholesterol in 
the internal membranes may also interfere with integral membrane proteins, 
induce apoptosis, and initiate a pro-inflammatory response (Maxfield 2005). 
Therefore, intracellularly accumulating cholesterol is re-esterified in the 
cytoplasm by acyl-coenzyme A:cholesterol acyltransferase (ACAT), which 
esterifies cholesterol with fatty acids, preferably with oleate, and the formed 
cholesteryl esters are stored in cytosolic lipid droplets, which are also called 
lipid bodies (Brown 1986). If large amounts of lipoprotein particles are 
internalized into macrophages, the lipid droplets eventually occupy most of the 
cytoplasm, creating a foam cell.  
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The cholesteryl esters of intracellular lipid droplets are continually hydrolyzed 
by neutral cholesteryl ester hydrolase, which together with ACAT creates a 
futile cycle of hydrolysis and re-esterification that wastes ATP (Brown 1980). 
The lipid droplets also contain triglycerides, signifying that also fatty acids are 
stored as esters (Mattsson 1993, Boström 2006). The storage of triglycerides 
may result from the transmembrane translocation of fatty acids. This involves a 
number of membrane-associated fatty acid-binding proteins (FABPs) and 
albumin binding proteins that function as acceptors for fatty acids released 
from albumin or from lipoprotein particles (Glatz 1997). The direction of fatty 
acid migration through the plasma membrane is likely regulated by the 
transmembrane gradient of fatty acid concentration, and the fatty acids may 
diffuse across the phospholipid bilayer in protonated form (Pownall 2003). 
From the plasma membrane the fatty acids could be transported to the sites of 
oxidation or esterification (Stremmel 2001).  
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III. AIMS OF THE STUDY  
Lipoprotein particles are known to undergo lipolytic modification, aggregate 
and fuse, bind to proteoglycans, and be taken up by monocyte-derived 
macrophages. These events are of importance in the selective lipid retention 
and accumulation within the intimal layer of the arterial wall. However, only a 
few studies address the effects of local extracellular acidity, present in the 
advanced atherosclerotic lesions, on the atherogenicity of the various apoB-
100-containing lipoprotein classes. Therefore, the aim of the present study was 
to investigate whether acidic pH has an effect on the atherogenicity of 
lipoprotein particles that are able to enter the arterial intima.  
The following specific questions were asked and answered:  
1. Could acidic pH increase lipoprotein lipolysis by sPLA2–V enzyme? If 
so, does the acidity influence the accumulation of highly bioactive lipolytic 
products in LDL particles?  
2. What kinds of lipolysis-induced changes occur on the lipoprotein particle 
surface structure in acidic conditions? Will these changes promote 
lipoprotein particle aggregation and fusion? 
3. Could lipolysis by sPLA2–V enzyme, together with acidic pH, promote 
binding of the lipoprotein particles to arterial proteoglycans? 
4. How do lipolysis by sPLA2–V enzyme and acidic pH influence the uptake 
and degradation of lipoprotein particles by human monocyte-derived 
macrophages? 
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IV. MATERIALS AND METHODS 
The different methods used in this thesis and their use in the three original 
publications are summarized in Table 2. These techniques have been described 
in more detail in the Methods sections of the original publications. If a more 
detailed description of the method has been published elsewhere, the reference 
is provided in Table 2.  
Table 2. Methods used in the original publications I-III 
Method Used in 
publications 
Reference 
Binding and uptake of lipoproteins by 
macrophages 
I, III (Goldstein 1983) 
Extraction and purification of aortic 
proteoglycans 
I, III (Hurt-Camejo 1990, 
Öörni 1997)  
High pressure liquid chromatography III  
3H-labeling of lipoproteins I, III (Bolton 1973) 
Isolation and culture of human monocytes I, III (Saren 1996) 
Isolation of LDL, IDL, and sVLDL 
lipoproteins 
I, III (Havel 1955, Radding 
1960, Lindgren 1972, 
Mahley 1979, Redgrave 
1979) 
Lipoprotein binding to proteoglycans I, III  
MD-simulations II (Berendsen 1995, van 
Gunsteren 1996, Lindahl 
2001)  
Modification of lipoproteins I, III  
NMR-spectroscopy I (Soininen 2005, 
Mierisová 2001, 
Soininen 2007) 
Thin layer chromatography I  
 
Lipoprotein isolation 
Human VLDL (d < 1.006 g/ml), IDL (d = 1.006−1.019 g/ml), and LDL (d = 
1.019−1.050 g/ml) were isolated from plasma (from the Finnish Red Cross), 
donated by healthy volunteers, using sequential ultracentrifugation in the 
presence of 3 mmol/L EDTA. Small VLDL (Sf 20–175) was isolated from the 
VLDL fraction by discontinuous density gradient ultracentrifugation. Isolated 
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lipoproteins were dialyzed against a solution containing 1mM EDTA and 
150mM NaCl (pH 7.4).  
3H-labeling of lipoproteins 
3H-labeled lipoproteins, 3H-LDL, 3H-IDL, and 3H-sVLDL were prepared by 
labeling the protein components according to the adapted Bolton-Hunter 
procedure, using the N-succinimidyl-3H-propionate as a reagent. To obtain 
sPLA2-V−modified 3H-LDL, 3H-IDL, and 3H-sVLDL, 3H-labeled lipoproteins 
were lipolyzed with sPLA2–V as described below.  
Modification of lipoproteins by phospholipolysis 
Lipolytic modifications of the lipoproteins were performed using either bee 
venom PLA2 or human recombinant sPLA2-V enzymes. For lipolysis of LDL 
with bee venom PLA2, the enzyme was first coupled to HiTrap NHS-activated 
Sepharose HP in a 1 ml column according to the manufacturer’s instructions. 
LDL in PBS was added to the PLA2-Sepharose and incubated at +37°C for 2 h. 
Sepharose-bound PLA2 was removed by centrifugation and the supernatant 
containing PLA2-modified LDL was collected. Lipolysis of LDL, IDL, and 
sVLDL lipoproteins with sPLA2-V enzyme was performed by incubating the 
lipoproteins for 18h at +37°C with 100-130 ng/ml of sPLA2-V in a buffer (20 
mM HEPES/MES/PIPES, 5 mM CaCl2, and 150 mM NaCl, 2% (w/v) BSA), at 
pH 7.5, 7.0, 6.5, 6.0 or 5.5. Lipolysis was terminated by the addition of EDTA 
or enzyme inhibitor compound 12e (6,7-benzoindole). After these 
phospholipolytic modifications, the degrees of lipoprotein phospholipolysis 
were determined with the NEFA-C-kit, which measures the amount of non-
esterified free fatty acids in a sample.  
Extraction and purification of aortic proteoglycans 
Proteoglycans from the intima-media of human aortas were obtained at autopsy 
within 24 h of accidental death. The following is a brief summary of that 
process: proteoglycans were extracted from intima-media at 4°C for 24 h with 
15 volumes of buffer containing 6 M urea and protease inhibitors. After 
extraction, the mixture was centrifuged at 100 000 g for 60 minutes. The 
supernatant was diluted with 6 M urea to give a final concentration of 0.25 M 
NaCl and loaded on a HiTrap Q column. The proteoglycans were eluted with a 
linear gradient of 0.25 M to 1.0 M NaCl, and the peaks at 280 nm were 
collected, dialyzed against water, and lyophilized. Glycosaminoglycans were 
quantified, and the amounts of proteoglycans were expressed in terms of their 
glycosaminoglycan content.  
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Lipoprotein binding to proteoglycans 
Lipoprotein-proteoglycan interactions were investigated with proteoglycan-
affinity chromatography and with proteoglycan coated microtiter well assays. 
To prepare human aortic proteoglycan-affinity column, human aortic 
proteoglycans (0.7 mg/ml) were coupled to a NHS-activated HiTrap column (5 
ml), as described in the manufacturer's instructions. Native or sPLA2-
V−modified lipoproteins were injected (0.4 ml at 2.0 mg/ml) into the 
proteoglycan-column that had been equilibrated with buffer containing 10 mM 
HEPES for pH 7.5 or 10 mM MES for pH 5.5, 2 mM CaCl2 and 2 mM MgCl2. 
The material bound to the column was eluted with a gradient of NaCl. The 
elution of the samples was monitored by UV absorbance at 280 nm, and the 
accuracy of the gradient was monitored by measuring change in conductivity.  
To measure lipoprotein binding to proteoglycans in a microtiter well assay, the 
wells of polystyrene 96-well plates were coated with human aortic 
proteoglycans (50 µg/ml in PBS) or BSA (5 mg/ml) by overnight incubation at 
+4 °C. The proteoglycan-coated wells were measured to contain about 250 ng 
of proteoglycans per well, and the wells coated with BSA served as controls in 
experiments. To measure lipoprotein binding, native or sPLA2-V−modified 
lipoproteins (0.5 mg/ml) were added to proteoglycan- or BSA-coated wells. 
The plates were incubated for 1 h at +37 °C in a buffer containing 1% BSA, 
150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2 and either 10 mM MES (pH 5.5) or 
10 mM HEPES (pH 7.5). After incubation, the wells were washed three times 
with a buffer containing 50 mM NaCl, 2 mM CaCl2, 2 mM MgCl2 and either 
10 mM MES (pH 5.5) or 10 mM HEPES (pH 7.5). The amounts of 
proteoglycan-bound lipoproteins were determined by measuring the amounts of 
cholesterol in each well.  
NMR-spectroscopy 
For the nuclear magnetic resonance (NMR) experiments, LDL (0.5 mg/ml) 
samples were prepared into a NMR-buffer containing D2O, lipolyzed, pH 
adjusted to pH 7.5, 7.0, 6.5, 6.0, or 5.5, and NMR data acquired in the presence 
of fatty acid free human serum albumin (2%, w/v). The 1H NMR data were 
obtained at 37 °C with a Varian Unity INOVA 800MHz spectrometer equipped 
with a 1H/15N/13C triple-resonance probe head. Acquisition time of 5.0 s and a 
relaxation delay of 1.0 s were used with a 90? flip angle, 8.8 kHz sweep width 
and 384 transients. The external tube containing the reference substance, 
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(sodium 3-trimethylsilyl[2,2,3,3-d4]propionate (TSP) 40 mmol/l, MnSO4 0.6 
mmol/l in 99.8% D2O), was placed coaxially into the NMR sample tube 
containing 450µl of each sample. Prior to Fourier transformation, the measured 
free induction decays (FIDs) with 64 k data points were zero filled and 
multiplied by an exponential window function with a line-broadening of 0.5 
Hz.  
PERCH NMR software was used for all data pre-processing steps as well as for 
the following lineshape fitting analyses. Each spectrum was scaled according 
to the area of the corresponding TSP reference signal. Even though the NMR 
spectral shapes for the FFA-containing albumin and PLA2-modified LDL were 
very similar at all pH conditions, an individual model lineshape was generated 
for them at each pH. These kinds of model lineshapes depict invariant spectral 
characteristics for molecular compounds and can be used in the analyses of 
component mixtures. In this particular case, the above-mentioned model 
lineshapes were used to analyze the 1H NMR spectra for the mixtures of PLA2-
modified LDL and FFA-free albumin at various pH conditions. At each pH 
condition, comparison of the spectral analysis for the 1H NMR spectrum of the 
mixture to that of the spectrum for the PLA2-modified LDL (without albumin) 
lead to the information on the redistribution of FFAs and lysoPCs due to the 
presence of albumin. 
Isolation and culture of human monocytes 
Human monocytes were isolated from buffy coats by centrifugation in Ficoll-
Paque gradient. Washed cells were resuspended in DMEM supplemented with 
penicillin and streptomycin, counted, and plated on cell culture wells. After one 
hour at +37°C, the non-adherent cells were removed by washing with PBS and 
the medium was replaced with macrophage-serum free medium (SFM), 
supplemented with antibiotics. Either 10 ng/ml of granulocyte-macrophage 
colony-stimulating factor (GM-CSF) or 50 ng/ml of macrophage colony- 
stimulating factor (M-CSF) was used. Experiments were started when 
monocytes had been cultured for 8 days in the presence of the cytokines and 
had thus been differentiated into mature macrophages. 
Uptake of lipoproteins by monocyte derived macrophages 
Before the experiments, the culture medium was replaced with custom-made 
HyQ DME/HIGH Glucose medium (HyClone) having a pH of 7.5, 6.5 or 5.5, 
and containing antibiotics and 4 mM L-glutamine. After incubation for 1 h, 3H-
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labeled lipoproteins were added to macrophage cultures. After a 5 h incubation 
time, the media and cells were collected for further analysis. 
Lipoprotein uptake by macrophages was determined by measuring the 
degradation and cell association of 3H-labeled lipoproteins. Lipoprotein 
degradation was quantified by the measurement of trichloroacetic acid-soluble 
(TCA) 3H-radioactivity from the incubation media. To remove any cell-
surface-bound lipoprotein particles, heparin was added to the cells, and the 3H-
radioactivity of the heparin incubation medium was measured. The intracellular 
amounts of 3H-labeled lipoproteins were measured by lysing the cells with 
NaOH, after which 3H-radioactivities, giving the intracellular lipoprotein 
amounts, were measured. 
Molecular dynamics simulations 
Three lipid bilayer systems were simulated for 50 ns using the GROMACS 
3.2.1 simulation package. In particular, the fully hydrolyzed 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine bilayers with varying protonation states of 
the liberated fatty acids mimicked three different pH values: 9.0, 7.5, and 5.5. 
Thus, bilayers represented changes in membrane structures going from alkaline 
to acidic values. After carrying MD-simulations, the simulation trajectories 
were analyzed to achieve computational membrane properties. Selected 
physical properties of these three systems were calculated as an average of the 
last 30 ns of the simulation trajectories. Physical properties that were calculated 
included: chain structure, lateral pressure profile across the membrane, area per 
headgroup, and electron density profiles for the whole system, water, lysoPC 
and fatty acid molecules, as well as for phosphorus atoms.  
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V. RESULTS AND DISCUSSION 
1. LIPOPROTEIN LIPOLYSIS  
1.1 Increased lipolysis at acidic pH 
Plasma lipoproteins contain fatty acids stored in triglycerides and in cholesteryl 
esters, and as surface monolayer components in the side chains in 
phospholipids and sphingolipids as well as some amounts of free fatty acids. 
The hydrolysis and re-esterification of these fatty acids plays an important role 
in many physiological processes. The relatively new discovery of a role for 
PLA2 enzymes in modification of plasma lipoproteins provides a seemingly 
endless array of potential biological functions that is only beginning to be 
appreciated.  
Previously, acidic pH and dilution have been shown to enhance PLA2-activity 
in human blood plasma (Costello 1990). Since intimal fluid is an ultrafiltrate of 
plasma, and, accordingly, the plasma-derived proteins contained in it are 
diluted (Smith 1990), it is conceivable that PLA2-activity is higher in the 
intimal fluid. Most of the atherogenic apoB-100-containing lipoproteins are 
also able to enter the arterial intima and so are present in the intimal fluid. We 
hypothesized that the lipoprotein particles are exposed to acidic conditions and 
to hydrolysis by PLA2 enzymes in the deep areas of advanced atherosclerotic 
lesions. We studied, in vitro, the effect of acidic pH on the activity of one 
member of the secretory PLA2 family, sPLA2-V, present in the deep acidic 
areas of atherosclerotic lesions (Kimura-Matsumoto 2008, Rosengren 2006b), 
toward lipoproteins.  
We found that the activity of sPLA2-V against apoB-100-containing LDL, IDL, 
and sVLDL particles increased at acidic pH (Figure 2, in paper III). When 
compared to lipolysis at pH 7.5, the degree of lipolysis of all these lipoproteins 
increased at pH 5.5; LDL by 1.6-fold, IDL by 1.8-fold, and of sVLDL by 1.3-
fold (Figure 2, in paper III). Although sPLA2 enzymes generally have a neutral 
pH optimum, the sPLA2-V also avidly hydrolyzed lipoprotein particles at 
acidic pH, suggesting that higher amounts of lipolytic products may be formed 
by the action of sPLA2-V enzyme in the local acidic areas of the arterial intima.  
The activity of sPLA2 enzymes is largely regulated by their ability to bind to 
phospholipid membranes, and sPLA2-V has a unique, relatively high affinity 
for anionic and charge-neutral phospholipid surfaces (Lambeau 2008, Winget 
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2006). Low pH can induce headgroup dehydration by neutralizing the 
negatively charged headgroup regions, reducing the effective headgroup size. 
Hence, at acidic pH, the increased proton concentration could reduce the 
phospholipid headgroup size and enhance the charge-neutral character of PC-
rich membranes, in doing so, increase the affinity of sPLA2-V to its substrate. 
Indeed, the transition of phospholipid membrane from one phase toward 
another can be induced by changes in pH, ion concentrations, membrane 
potential, membrane proteins and hydration (Kinnunen 1991). The lateral 
pressure also decreases sharply at the transition between gel phase and fluid 
phase (Fulford 1980). Thus, the properties of phospholipid monolayer on the 
surface of lipoprotein particles change when moving from neutral to acidic pH, 
and these changes may be more favorable for the action of sPLA2-V enzyme. 
However, reducing the headgroup size may also increase the ordering of acyl 
chains (in Paper II), which together with stronger lipid-lipid interactions may 
decrease the efflux propensity of the phospholipid substrate from the 
membrane into the catalytic site of several PLA2 enzymes (Haimi 2010). In 
conclusion, in spite of the fact that the potential phospholipid efflux propensity 
may decrease, the enhanced ability of sPLA2-V to bind to its more charge-
neutral substrate could increase its activity at acidic pH. 
To summarize, in advanced human atherosclerotic lesions, sPLA2-V is found 
particularly in the deep areas of the lesions (Kimura-Matsumoto 2008, 
Rosengren 2006b), where intima is often hypoxic (Sluimer 2008), and, 
accordingly, intimal fluid is acidic. Our findings suggest that the lipolytic 
modification of apoB-100-containing lipoproteins, sVLDL, IDL, and LDL, by 
sPLA2-V can be increased at acidic pH, and more bioactive lipolytic products, 
lysoPCs and FFAs, could be locally produced in the advanced atherosclerotic 
plaques.  
1.2 LDL retains hydrolytic products at acidic pH  
The most abundant plasma protein, albumin, may bind the formed lipolytic 
products in the intima and transfer them back to the circulatory system. The 
concentration of albumin present in the intimal fluid has been estimated to be 
about half of its plasma concentration (Smith 1990). We studied the effect of 
pH on the ability of albumin to remove the lipolytic products from the 
lipolyzed LDL particles. Using 1H NMR-spectroscopy (Soininen 2007) we 
could directly examine the transfer of FFAs and lysoPCs to albumin in the 
LDL-albumin incubation mixtures. The transfer of lipolytic products was also 
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studied by separating albumin from LDL incubation mixtures by 
ultracentrifugation, and by measuring the amounts of retained lipolytic 
products, FFAs and lysoPCs, in LDL particles. We found that the amount of 
FFAs remaining in the LDL particles depended on the pH: acidity increased the 
amount of FFAs that remained LDL-bound (Figure 1A, in paper I and Table 1, 
in paper I). The amounts of lysoPCs were also determined and acidity also 
increased the percentage of lysoPCs that remained LDL-bound (Figure 1B, in 
paper I and Table 1, in paper I). Thus, at acidic pH, the ability of physiological 
concentration of albumin to sequester FFAs and lysoPCs from sPLA2-
V−modified LDL particles was decreased, and the lipolytic products were 
retained in LDL particles. 
The observed pH-dependent transfer of FFAs to albumin may result from the 
property of albumin to preferably bind FFAs in their anionic form (Spector 
1975, Hamilton 2002). Since the pKa of FFAs in a phospholipid membrane is 
approximately 7.5 (Small 1984), about half of the PLA2-generated FFAs in 
LDL are in anionic form at pH 7.5, while all of them are uncharged at pH 5.5. 
Therefore, as acidity decreases the affinity of albumin for the FFAs, the 
transfer of the lipolytic products from lipolyzed LDL to albumin also 
decreases, and FFAs are retained in the lipolyzed LDL particles.  
Albumin consists of 585 amino acids and has a rather small size (He 1992). It 
can easily pass through the intima and reach the lymphatic capillaries 
originating in medial layer of the arterial wall (Smith 1990). Therefore, in early 
atherosclerotic lesions in which the extracellular pH is physiologic, albumin 
has the potential to carry the PLA2-generated FFAs and lysoPCs away from the 
arterial intima back to the circulation. In contrast, the local acidity of advanced 
atherosclerotic lesions may block this carrier function of albumin. Importantly, 
the physiological concentration of albumin in blood serum varies between 
individuals ranging from about 20 to about 50 mg/ml (Nelson 2000), and so the 
physiological concentration of albumin in the intima also must vary among 
individuals, constituting about half of its plasma concentration (Smith 1990). 
Thus, the differences in the intimal concentration of albumin between 
individuals may have an effect on the transfer of lipids to albumin. In our 
experimental system, a decrease in the albumin concentration was found to 
increase the accumulation of the lipolytic products in LDL particles. If this also 
applies to the arterial intima in vivo, PLA2-induced modification of LDL 
particles in the acidic intimal fluid would have more atherogenic potential in 
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individuals with low serum albumin concentrations compared to individuals 
with high serum albumin concentrations. Hence, the function of albumin as a 
scavenger for FFAs and lysoPCs may partly explain the observation that low 
levels of serum albumin associate with an increase in CHD incidents (Nelson 
2000). 
In conclusion, although elevated cholesterol levels are a recognized risk factor 
for atherosclerosis, the quality of lipids in lipoprotein particles are also 
currently recognized as a risk factor for the development of atherosclerosis 
(Matsumoto 2007). Several phospholipid-derived bioactive compounds are 
generated from lipoprotein particles by phospholipases and by oxidation, 
including fatty acids, lysophospholipids, and phosphatidic acids. These lipids, 
if retained in LDL particles at acidic pH, may have various atherogenic effects 
upon intimal cells (Schmitz 2009, Matsumoto 2007, Macphee 2006, Wilensky 
2009).  
1.3 PLA2-hydrolysis induced changes on the surface monolayer 
The monolayer covering the lipoprotein particles is mainly composed of PCs, 
and the hydrolysis of PC by PLA2 enzyme generates lysoPCs and FFAs. To 
gain information at molecular level on the effects of PLA2-induced changes at 
acidic pH, we used molecular dynamics (MD) simulations to simulate three 
fully hydrolyzed model membranes that may reflect a physiological 
nanodomain on the surface of lipoprotein particles.  
We found that acidity changes the properties of PLA2-lipolyzed membrane. At 
acidic pH, the membrane leaflets were found to be laterally more tightly 
packed (Figure 2 and Figure 3, in paper II); moreover, the spontaneous 
curvature of the opposing monolayer leaflets became negative (Table 2, in 
paper II). When applied to the monolayer covering the lipoprotein particles, 
these properties suggest that the tendency of lipoprotein particles to fuse is pH-
dependent.  
Lipoprotein particles can be considered as spherical lipid droplets of a given 
volume. At neutral pH, the FFAs on the surface of droplets are partially 
negatively charged and more hydrophilic. Therefore, they tend to lower the 
surface tension of an oil-water interface. At low pH values, however, the FFAs 
are uncharged and less hydrophilic than at neutral pH, and, in such a droplet, 
acidity could lead to increased surface tension. The increased surface tension 
can return to the original value if lipid molecules absorb on the surface, or if 
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the particle size decreases. However, these two processes are likely to be too 
slow in order to decrease the surface tension of a droplet, when compared to 
the rapid fusion of membranes induced by increased surface tension (Lyklema 
J. 2000). Taken together, our results suggest that local extracellular acidity and 
lipoprotein lipolysis by PLA2 may promote lipoprotein fusion by inducing 
negative spontaneous curvature to the lipolyzed monolayer covering 
lipoprotein particles, and also by increasing the surface tension of the 
lipoprotein particles. 
2. LIPOPROTEIN RETENTION 
2.1 Binding of lipoproteins to proteoglycans 
In the intima, lipoprotein particles can become modified and bound to the 
arterial proteoglycans. The subendothelial retention of lipoprotein particles is 
the initiating event in atherosclerosis, and, once retained, the lipoprotein 
particles provoke a cascade of responses that lead to atherosclerosis in a 
previously non-lesional artery (Tabas 2007).  
To determine if acidic pH and the lipolysis of lipoprotein particles with sPLA2-
V enzyme can have an effect on the binding of lipoproteins to proteoglycans, 
we used microtiter wells coated with proteoglycans isolated from the intima-
media of human aortas. We found that acidity increased the amounts of 
proteoglycan-bound native LDL, IDL, and sVLDL (Figure 3, in paper III). 
Thus, at pH 5.5, there was 270-fold increase in the binding of native LDL, a 
60-fold increase in the binding of native IDL, and a 140-fold increase in the 
binding of native sVLDL to proteoglycans, as compared to binding results at 
pH 7.5. Additionally, we found that at acidic pH 5.5, lipolysis of lipoprotein 
particles by sPLA2-V further increased the amounts of proteoglycan-bound 
lipoproteins (Figure 3, in paper III). Thus, at pH 5.5, sPLA2-V−LDL bound 
1.9-fold, sPLA2-V−IDL bound 1.7-fold, and sPLA2-V−sVLDL bound 2.0-fold 
more than native lipoprotein particles at the same pH. 
In conclusion, we found that acidic pH induced a dramatic increase in the 
binding of native and sPLA2-V-lipolyzed apoB-100-containing plasma 
lipoproteins, sVLDL, IDL, and LDL particles, to human aortic proteoglycans. 
The acidity-induced increase in the binding of all three classes of native 
lipoprotein particles to human aortic proteoglycans can be mediated via the 
ionic interactions between the negatively charged glycosaminoglycan chains of 
the proteoglycans and the positively charged amino acids lysine and arginine of 
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the apoB-100 of the lipoprotein particles, which has been previously observed 
in the case of LDL (Sneck 2005). In contrast, PLA2-lipolysis increases the 
binding of LDL to proteoglycans due to an alteration in the conformation of 
apoB-100, which exposes a new proteoglycan-binding site (Flood 2004). This 
binding site may also be responsible for the observed increased binding of the 
PLA2-lipolyzed IDL and sVLDL particles to proteoglycans. Moreover, at low 
pH 5.5, the FFAs of lipoproteins are protonated (Kanicky 2002), which 
increases the charge difference between the lipoprotein particles and the 
negatively charged proteoglycans. This increase in electrostatic interactions 
may lead to stronger interactions between the apoB-100-containing plasma 
lipoprotein particles and the proteoglycans at acidic pH.  
2.2 Affinity of lipoproteins for proteoglycans 
Using proteoglycan-affinity column chromatography, we eluted the 
proteoglycan column bound lipoproteins with increasing salt concentration. We 
found that, both at neutral and at acidic pH, native LDL (Figure 4C, in paper 
III) eluted from the column as a single peak, whereas native IDL (Figure 4B, in 
paper III) and sVLDL (Figure 4A, in paper III) eluted in two or three peaks, 
revealing heterogeneity among the IDL and sVLDL particle classes. We also 
found that the binding affinity of the LDL, IDL, and sVLDL particles was 
significantly higher at acidic pH than at neutral pH. Thus, the major fraction of 
all studied apoB-100-containing lipoproteins required a supraphysiological 
NaCl concentration (400 mM) for detachment from the human aortic 
proteoglycans. Regarding lipolysis, sPLA2-V had the largest effect on the 
affinity of LDL for proteoglycans (Figure 4C, in paper III), while its effect on 
the affinity of VLDL (Figure 4A, in paper III) and IDL (Figure 4B, in paper 
III) for proteoglycans was smaller.  
In all three lipoprotein classes, sVLDL, IDL, and LDL, lower amounts of 
particles failed to bind to proteoglycans at acidic pH than at neutral pH (Figure 
4A-C, in paper III). This indicated that a fraction of the lipoproteins not 
binding at pH 7.5 did bind at pH 5.5, which further implicated their higher 
binding affinity for proteoglycans at acidic pH. Taken together, we found that 
acidity had dramatic effect on the binding affinity of apoB-100 containing 
lipoproteins for proteoglycans, which suggests that acidity may increase the 
proteoglycan binding of the three classes of lipoprotein particles in 
atherosclerotic lesions. 
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2.3 Effect of small apolipoproteins on sVLDL binding to proteoglycans 
The binding of LDL, IDL, and sVLDL to proteoglycans is mainly mediated by 
the interaction between apoB-100 and proteoglycans. In addition, IDL and 
VLDL particles also contain additional small apolipoproteins, such as apoC-III 
and apoE, which are potentially capable of influencing the proteoglycan-
lipoprotein interaction, since the apoE moiety of lipoproteins has been shown 
to bind to proteoglycans (Camejo 1988). 
We used proteoglycan-affinity column chromatography to further study the 
relationship between the apoC-III and apoE contents of the sVLDL particles 
and their relative affinities for proteoglycans. As discussed above, sVLDL 
eluted from the proteoglycan column in three populations (Figure 4A, in paper 
III). From these three populations, we analyzed the apoC-III and apoE contents 
and found that the sVLDL particles with low affinity had high contents of these 
two apolipoproteins (Figure 5A-B, in paper III), and the highest apoC-III and 
apoE contents were found in sVLDL particles that had the lowest affinity 
toward proteoglycans at acidic pH. Notably, these particles were not able to 
bind to proteoglycans even at acidic pH, which favors the electrostatic 
interactions between lipoproteins and proteoglycans. We also used an anti-
apoE affinity chromatography to separate apoE-enriched particles and found 
that the separated particles showed only minor binding to proteoglycans in our 
proteoglycan coated microtiter well assay (Figure 6, in paper III).  
To summarize, we found that the particles with the lowest affinity for human 
aortic proteoglycans had the highest amounts of apoE and apoC-III. In contrast, 
it has previously been shown that the binding of proteoglycans to VLDL, 
derived from different healthy donors, correlates positively with the apoC-III 
content of this lipoprotein class (Olin-Lewis 2002). This correlation is 
surprising since apoC-III does not itself bind to proteoglycans, and addition of 
purified apoC-III to apoB-containing lipoproteins in vitro has been shown to 
inhibit the lipoproteins binding to proteoglycans (Olin-Lewis 2002). It has been 
suggested that the previously observed positive correlation between apoC-III 
content and the proteoglycan binding to lipoproteins relies on apoC-III-
dependent conformational changes in apoB-100 (Olin-Lewis 2002, Hiukka 
2009). Our findings, showing that lipoproteins having the highest apoC-III 
content actually have the lowest affinity for proteoglycans, favor the view that, 
if there is a high apoC-III content in the total particle population of sVLDL 
lipoprotein class, it may reflect some other intrinsic property, that affects both 
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their apoC-III content as well as their binding to proteoglycans. Such an 
intrinsic property can be particle size, as apoC-III and apoE are more enriched 
on large VLDL particles (Marcel 1988, Shin 2010), and large VLDL particles 
have been shown to have a lower affinity for proteoglycans than small VLDL 
particles (Anber 1997). Additionally, higher apoE and apoC-III contents at the 
lipoprotein particle surface may reflect the surface pressure of these lipoprotein 
particles, since the association of small apolipoproteins to the particle surface is 
sensitive to the surface pressure of the phospholipid monolayer covering the 
particles (McNamara 1996). Altered surface pressure can result from changes 
in lipid composition on the particle surface, due to extensive modifications or 
abnormal endogenous lipid constituents. The addition of some small 
apolipoproteins to the surface may return the surface tension to the normal 
value, without changing the properties of lipids. 
In conclusion, we observed that LDL, IDL, and sVLDL particles consist of 
heterogeneous populations of lipoprotein particles, with lower and higher 
binding affinities for human aortic proteoglycans. We also observed that the 
sVLDL class of lipoprotein particles is heterogeneous in apoE and apoC-III 
contents, suggesting that the apoE and apoC-III contents in a particle reflect an 
intrinsic property of the particle that also affects binding affinity for human 
aortic proteoglycans.  
3. INTRACELLULAR LIPID ACCUMULATION 
3.1 Lipoprotein uptake by macrophages 
At all stages of atherosclerosis, arterial macrophages take up lipoproteins by an 
unregulated mechanism leading to intracellular lipid droplet accumulations. 
Under a microscope, these cells have a foamy appearance and are called “foam 
cells.”  
The present investigations revealed that lipoprotein lipolysis by sPLA2-V 
enzyme leads to increased particle uptake by macrophages at acidic pH and to 
foam cell formation (Figure 4, in paper I and Figure 7, in paper III). First, with 
macrophages differentiated with GM-CSF, we found that sPLA2-V−modified 
LDL is avidly taken up by macrophages at acidic pH (Figure 4, in paper I). 
Thus, the elevated amounts of cell-associated and degraded sPLA2-V-modified 
LDL particles were 1.5-fold higher at pH 6.5, and 3.5-fold higher at pH 5.5, 
when compared to levels at pH 7.5. Secondly, with the macrophage phenotype 
predominating in the arterial intima, i.e., macrophages differentiated with M-
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CSF, we found that acidity did not increase the intracellular accumulation of 
native LDL, IDL, and sVLDL particles (Figure 7A-C, in paper III). In fact, 
acidity decreased the uptake of native sVLDL (Figure 7A, in paper III). This 
observed decrease in the uptake of native sVLDL by macrophages at acidic pH 
may depend on the properties of VLDL receptor. Thus, at neutral pH, the 
apoE-containing lipoproteins can bind to the VLDL receptor (Takahashi 2004), 
but the lipoprotein ligands are released from the LDLR family at low pH 
(Fisher 2006, Rudenko 2002), which may partly explain the observed 
decreased uptake of sVLDL particles. 
We also found that lipolysis with sPLA2-V of all three lipoprotein classes 
(LDL, IDL, and sVLDL particles) resulted in their increased uptake and 
increased intracellular lipid accumulations in macrophages (Figure 7A-C, in 
paper III). Thus, in our experimental system, macrophages were found to 
avidly take up sPLA2-V-modified LDL, IDL, and sVLDL lipoprotein particles 
both at neutral and at acidic pH (Figure 7A-C, in paper III). The possible 
mechanism for the increased lipid uptake at acidic pH is not likely to involve 
the LDLR-related family of receptor proteins or LRP-1, because of their nature 
to bind ligands at neutral pH (Fisher 2006, Rudenko 2002, Moestrup 1990). 
However, since the binding strength of sPLA2-V-modified LDL to 
proteoglycans is increased at acidic pH (Figure 3B, in paper I and Figure 3, in 
paper III), it is possible that the observed increased lipoprotein uptake depends 
on increased binding to cell-surface proteoglycans. Indeed, recently, at neutral 
pH, the uptake of sPLA2-V-modified LDL was shown to depend on cell-
surface proteoglycans, particularly on syndecans (Boyanovsky 2005, 
Boyanovsky 2009a). We confirmed this observation by first treating 
macrophages with a combination of chondroitinase and heparinase and found 
that the binding of LDL to cell-surface was after this treatment decreased at 
acidic pH.  
In conclusion, acidity failed to increase the uptake of native lipoproteins by 
human monocyte-derived macrophages. In contrast, premodification of all 
three lipoprotein classes with the sPLA2-V enzyme was able to induce such 
modifications at the lipoprotein particle surface that they were internalized by 
macrophages, both at neutral and at acidic pH values. The combined effects of 
both acidity and lipoprotein lipolysis by sPLA2-V enzyme may thus lead to 
intracellular lipoprotein accumulations.  
Results and Discussion 
52  
4. FUTURE PERSPECTIVES 
To date, the most effective pharmacotherapy against atherosclerosis are statins, 
which are based on the principle that decreasing the amount of circulating LDL 
particles decreases the probability that they will enter, and be retained in, the 
arterial subendothelium. Ongoing improvements in this area include more 
aggressive lowering of LDL and other atherogenic lipoproteins in the plasma, 
and initiation of the therapy in high-risk individuals at an earlier age. However, 
statins alone, even in high doses, are not sufficient to fully prevent the 
progression of atherosclerosis in many susceptible individuals. Indeed, 
cardiovascular events continue to occur in two thirds of all patients on statin 
treatment, as has been shown by several large controlled clinical trials, 
including the Scandinavian Simvastatin Survival Study, the Cholesterol and 
Recurrent Events trial, the Air Force/Texas Coronary Atherosclerosis 
Prevention studies, and the Long-term Intervention with Pravastatin in 
Ischemic Disease study (Libby 2005). Thus, there a real need exists for a 
deeper understanding of the pathophysiological mechanisms by which 
lipoprotein particles in the intima accelerate the progression of atherosclerosis. 
The key initiating process in atherogenesis is the subendothelial retention of 
apoB-100-containing lipoproteins. New approaches, as future therapeutics, 
may include attempts to block the interaction of apoB-100-containing 
lipoproteins with the specific subendothelial matrix molecules that promote 
lipoprotein retention. The matrix-retained lipoprotein particles are prone to 
several types of modifications: oxidation, proteolysis and lipolysis. The 
blocking of molecules within the arterial wall that modify lipoprotein particles 
are potential therapeutic targets as well. Local biological responses to these 
retained and modified lipoproteins, including chronic inflammation and fatty 
streak formation, also promote the subsequent lesion development. 
There is ample evidence that enzymatic particle lipolysis, which can also be 
coupled to particle oxidation, is a particularly atherogenic process. Thus, 
significant amounts of lipids are stored as triglycerides in macrophages 
(Mattsson 1993), and hypoxia increases the amounts of cytosolic lipid droplets 
with increasing amounts of triglycerides (Boström 2006), suggesting that, in 
addition to cholesterol, fatty acids are taken up and stored by macrophages as 
triglycerides. However, because of the complexity of cellular lipid metabolism 
and its regulation, it has been difficult to establish a causal link between 
specific lipid mediators within the vessel wall and clinical events.  
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Recent discoveries suggest that lipoprotein particles can be extensively 
modified by sPLA2 and Lp-PLA2 enzymes, and blocking the action of these 
enzymes may represent a new approach to the treatment of atherosclerosis. 
Thus, it is not only the quantity of cholesterol circulating and able to enter the 
intima, but also the quality of various other lipids in lipoprotein particles, that 
can be strikingly atherogenic. The observed potential links between free fatty 
acids produced by sPLA2-V enzyme and the extracellular and intracellular 
accumulations of lipoprotein particles, which may lead to the development of 
foam cells in atherosclerosis, offer future targets for PLA2 inhibitors. Inhibitors 
that are specific for atherogenic PLA2 enzymes are the most promising, and the 
development of these inhibitors has become the focus of pharmacological 
research in this last decennium (Garcia-Garcia 2009, Oslund 2008). Currently, 
there are several ongoing Phase III clinical trials with the PLA2 inhibitors 
(Suckling 2009). These inhibitors are specific for Lp-PLA2, or for several 
forms of sPLA2s. There is an ongoing STABILITY trial with Darapladib 
(GlaxoSmithKline), which is an inhibitor of Lp-PLA2 (Riley 2009, Bui 2010). 
Varespladib (Anthera), inhibits the sPLA2-IIA, sPLA2-V and sPLA2-X, and 
there is an ongoing FRANCIS-ACS trial on patients with acute coronary 
syndrome (Karakas 2009). Thus, inhibitors of the enzymes that play critical 
roles in LDL modification are potential novel antiatherogenic drugs that could 
be used synergistically with statins. They may also offer new treatment options 
to those patients who fail to gain the full benefit from statin treatment.  
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VI. SUMMARY AND CONCLUSIONS  
This thesis aimed to elucidate some of the atherogenic effects of acidic pH on 
the apoB-100-containing lipoprotein accumulation in the arterial intima, with a 
specific focus on the role of sPLA2-V enzyme. Based on our findings and the 
above discussion, the following conclusions can be presented. Figure 5 
recapitulates the main findings in an illustrative way.  
 
 
 
 
 
  
 
 
 
 
 
 
Figure 5. Summary of the main findings of the thesis. (1) Acidity increases 
the apoB-100-containing lipoprotein particle lipolysis by sPLA2-V enzyme, 
and the lipolytic products, lysoPCs and FFAs, are retained in LDL 
particles. (2) At acidic pH, the tendency of the apoB-100-containing 
lipoprotein particles to fuse into extracellular lipid droplets increases after 
PLA2 hydrolysis. (3) Lipolysis by sPLA2-V enzyme and acidity increase the 
apoB-100-containing lipoprotein particle binding to extracellular matrix 
proteoglycans. (4) At acidic pH, the sPLA2-V-modified apoB-100-
containing lipoprotein particles are taken up by monocyte-derived 
macrophages, thus promoting the formation of foam cells.  
Current evidence suggests that the development of atherosclerosis culminates 
in a gradual increase in lipid deposition and ensuing chronic inflammation in 
the subendothelium (Williams 1995, Libby 2002). The subendothelially 
deposited atherogenic lipoproteins provide substrates for multiple modifying 
agents. The modified lipoproteins are subsequently taken up by locally 
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recruited macrophages, which are then converted into foam cells. Foam cells, 
in turn, are activated to produce various cytokines that promote and maintain 
the local inflammation (Boyanovsky 2010). The sPLA2 family of enzymes has 
been implicated in pro-atherosclerotic processes because of their hydrolyzing 
activities in the arterial intima (Rosenson 2009a), and because diet-induced or 
gene-induced hyperlipidemia in mice enhances the expression of sPLA2-V in 
aorta (Rosengren 2006b). Our results suggest that sPLA2-V enzyme can be 
considered a particularly atherogenic enzyme in the acidic microdomains of 
advanced atherosclerotic plaques. At acidic pH, sPLA2-V is able to hydrolyze 
plasma lipoprotein particles (papers I and III), thereby leading to increased 
amounts of retained bioactive hydrolysis products, FFAs and lysoPCs, in LDL 
particles (paper I). After lipolysis, the lipoprotein particles have a higher 
binding strength toward the arterial proteoglycans (papers I and III). The PLA2-
lipolyzed lipoprotein particles are also more prone to fuse at acidic pH, because 
of the altered, fusion-promoting properties of the surface monolayer of the 
lipolyzed particles (paper II). At acidic pH, the retained and hydrolyzed 
lipoprotein particles are taken up by monocyte-derived arterial macrophages, 
which tends to lead to the formation of foam cells (papers I and III).  
In conclusion, the extracellular acidic pH of advanced atherosclerotic lesions 
may provoke increased lipoprotein lipolysis. Furthermore, the lipolyzed 
particles strongly bind to arterial proteoglycans and are taken up by arterial 
macrophages. However, even though acidity strongly increased the binding of 
native lipoproteins to human aortic proteoglycans, it failed to increase the 
uptake of native lipoproteins by human monocyte-derived macrophages. In 
contrast, the premodification of all three lipoprotein classes with sPLA2-V 
enzyme was able to render such modifications at the lipoprotein particle 
surface that they were internalized by macrophages, both at neutral and acidic 
pH values. Hence, the combined effects of acidity and lipoprotein lipolysis by 
sPLA2-V enzyme may, together, lead to both intracellular and extracellular 
lipoprotein accumulations.  
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